000084263312/312026Q3FALSE35,285,062P1Yhttp://fasb.org/srt/2026#ChiefExecutiveOfficerMember http://fasb.org/srt/2026#PresidentMemberP2Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Ratetrs:casestrs:claimantstrs:number00008426332026-01-012026-09-3000008426332026-11-1200008426332026-09-3000008426332025-12-3100008426332026-07-012026-09-3000008426332025-07-012025-09-3000008426332025-01-012025-09-3000008426332024-12-3100008426332025-09-300000842633us-gaap:CommonStockMember2025-12-310000842633us-gaap:AdditionalPaidInCapitalMember2025-12-310000842633us-gaap:RetainedEarningsMember2025-12-310000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310000842633us-gaap:ParentMember2025-12-310000842633us-gaap:RetainedEarningsMember2026-01-012026-03-310000842633us-gaap:ParentMember2026-01-012026-03-310000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310000842633us-gaap:CommonStockMember2026-01-012026-03-310000842633us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310000842633us-gaap:CommonStockMember2026-03-310000842633us-gaap:AdditionalPaidInCapitalMember2026-03-310000842633us-gaap:RetainedEarningsMember2026-03-310000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310000842633us-gaap:ParentMember2026-03-310000842633us-gaap:RetainedEarningsMember2026-04-012026-06-3000008426332026-04-012026-06-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300000842633us-gaap:CommonStockMember2026-04-012026-06-300000842633us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300000842633us-gaap:ParentMember2026-04-012026-06-300000842633us-gaap:CommonStockMember2026-06-300000842633us-gaap:AdditionalPaidInCapitalMember2026-06-300000842633us-gaap:RetainedEarningsMember2026-06-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-3000008426332026-06-300000842633us-gaap:RetainedEarningsMember2026-07-012026-09-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-300000842633us-gaap:CommonStockMember2026-07-012026-09-300000842633us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300000842633us-gaap:CommonStockMember2026-09-300000842633us-gaap:AdditionalPaidInCapitalMember2026-09-300000842633us-gaap:RetainedEarningsMember2026-09-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300000842633us-gaap:CommonStockMember2024-12-310000842633us-gaap:AdditionalPaidInCapitalMember2024-12-310000842633us-gaap:RetainedEarningsMember2024-12-310000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000842633us-gaap:ParentMember2024-12-310000842633us-gaap:RetainedEarningsMember2025-01-012025-03-310000842633us-gaap:ParentMember2025-01-012025-03-310000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000842633us-gaap:CommonStockMember2025-01-012025-03-310000842633us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000842633us-gaap:CommonStockMember2025-03-310000842633us-gaap:AdditionalPaidInCapitalMember2025-03-310000842633us-gaap:RetainedEarningsMember2025-03-310000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000842633us-gaap:ParentMember2025-03-310000842633us-gaap:RetainedEarningsMember2025-04-012025-06-3000008426332025-04-012025-06-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300000842633us-gaap:CommonStockMember2025-04-012025-06-300000842633us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300000842633us-gaap:CommonStockMember2025-06-300000842633us-gaap:AdditionalPaidInCapitalMember2025-06-300000842633us-gaap:RetainedEarningsMember2025-06-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-3000008426332025-06-300000842633us-gaap:RetainedEarningsMember2025-07-012025-09-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300000842633us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000842633us-gaap:CommonStockMember2025-09-300000842633us-gaap:AdditionalPaidInCapitalMember2025-09-300000842633us-gaap:RetainedEarningsMember2025-09-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300000842633trs:AerospaceReportableSegmentMember2026-01-012026-09-300000842633trs:AerospaceReportableSegmentMember2026-03-162026-03-160000842633trs:ProductionTaxCreditsMemberus-gaap:SegmentDiscontinuedOperationsMember2026-07-012026-09-300000842633us-gaap:SegmentDiscontinuedOperationsMember2026-01-012026-09-300000842633us-gaap:SegmentDiscontinuedOperationsMember2025-01-012025-09-300000842633trs:ConsumercustomerendmarketMember2026-07-012026-09-300000842633trs:ConsumercustomerendmarketMember2025-07-012025-09-300000842633trs:ConsumercustomerendmarketMember2026-01-012026-09-300000842633trs:ConsumercustomerendmarketMember2025-01-012025-09-300000842633trs:IndustrialcustomerendmarketMember2026-07-012026-09-300000842633trs:IndustrialcustomerendmarketMember2025-07-012025-09-300000842633trs:IndustrialcustomerendmarketMember2026-01-012026-09-300000842633trs:IndustrialcustomerendmarketMember2025-01-012025-09-300000842633trs:RealignmentActionsMember2026-07-012026-09-300000842633trs:RealignmentActionsMember2026-01-012026-09-300000842633trs:RealignmentActionsMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-07-012026-09-300000842633trs:RealignmentActionsMemberus-gaap:CostOfGoodsAndServicesSold2026-01-012026-09-300000842633trs:RealignmentActionsMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-01-012026-09-300000842633trs:RealignmentActionsMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-07-012025-09-300000842633trs:RealignmentActionsMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-01-012025-09-300000842633trs:RealignmentActionsMember2025-01-012025-09-300000842633trs:GMTAerospaceMember2025-02-172025-02-170000842633trs:GMTAerospaceMember2025-02-170000842633trs:ArrowEngineMember2025-01-012025-09-300000842633trs:ArrowEngineMember2025-10-012025-12-310000842633trs:PackagingReportableSegmentMember2025-12-310000842633trs:SpecialtyProductsReportableSegmentMember2025-12-310000842633trs:PackagingReportableSegmentMember2026-01-012026-09-300000842633trs:SpecialtyProductsReportableSegmentMember2026-01-012026-09-300000842633trs:PackagingReportableSegmentMember2026-09-300000842633trs:SpecialtyProductsReportableSegmentMember2026-09-300000842633srt:MinimumMember2026-09-300000842633srt:MaximumMember2026-09-300000842633srt:MinimumMembertrs:UsefulLifeFiveToTwelveYearsMemberus-gaap:CustomerRelationshipsMember2026-09-300000842633srt:MaximumMembertrs:UsefulLifeFiveToTwelveYearsMemberus-gaap:CustomerRelationshipsMember2026-09-300000842633trs:UsefulLifeFiveToTwelveYearsMemberus-gaap:CustomerRelationshipsMember2026-09-300000842633trs:UsefulLifeFiveToTwelveYearsMemberus-gaap:CustomerRelationshipsMember2025-12-310000842633srt:MinimumMembertrs:UsefulLifeFifteenToTwentyfiveYearsMemberus-gaap:CustomerRelationshipsMember2026-09-300000842633srt:MaximumMembertrs:UsefulLifeFifteenToTwentyfiveYearsMemberus-gaap:CustomerRelationshipsMember2026-09-300000842633trs:UsefulLifeFifteenToTwentyfiveYearsMemberus-gaap:CustomerRelationshipsMember2026-09-300000842633trs:UsefulLifeFifteenToTwentyfiveYearsMemberus-gaap:CustomerRelationshipsMember2025-12-310000842633us-gaap:CustomerRelationshipsMember2026-09-300000842633us-gaap:CustomerRelationshipsMember2025-12-310000842633srt:MinimumMembertrs:UsefulLifeOneToFifteenYearsMemberus-gaap:OtherIntangibleAssetsMember2026-09-300000842633srt:MaximumMembertrs:UsefulLifeOneToFifteenYearsMemberus-gaap:OtherIntangibleAssetsMember2026-09-300000842633trs:UsefulLifeOneToFifteenYearsMemberus-gaap:OtherIntangibleAssetsMember2026-09-300000842633trs:UsefulLifeOneToFifteenYearsMemberus-gaap:OtherIntangibleAssetsMember2025-12-310000842633srt:MinimumMembertrs:UsefulLifeSeventeenToThirtyYearsMemberus-gaap:OtherIntangibleAssetsMember2026-09-300000842633srt:MaximumMembertrs:UsefulLifeSeventeenToThirtyYearsMemberus-gaap:OtherIntangibleAssetsMember2026-09-300000842633trs:UsefulLifeSeventeenToThirtyYearsMemberus-gaap:OtherIntangibleAssetsMember2026-09-300000842633trs:UsefulLifeSeventeenToThirtyYearsMemberus-gaap:OtherIntangibleAssetsMember2025-12-310000842633us-gaap:OtherIntangibleAssetsMember2026-09-300000842633us-gaap:OtherIntangibleAssetsMember2025-12-310000842633us-gaap:TrademarksAndTradeNamesMember2026-09-300000842633us-gaap:TrademarksAndTradeNamesMember2025-12-310000842633us-gaap:CostOfGoodsAndServicesSoldus-gaap:OtherIntangibleAssetsMember2026-07-012026-09-300000842633us-gaap:CostOfGoodsAndServicesSoldus-gaap:OtherIntangibleAssetsMember2025-07-012025-09-300000842633us-gaap:CostOfGoodsAndServicesSoldus-gaap:OtherIntangibleAssetsMember2026-01-012026-09-300000842633us-gaap:CostOfGoodsAndServicesSoldus-gaap:OtherIntangibleAssetsMember2025-01-012025-09-300000842633us-gaap:SellingGeneralAndAdministrativeExpenseus-gaap:CustomerRelationshipsMember2026-07-012026-09-300000842633us-gaap:SellingGeneralAndAdministrativeExpenseus-gaap:CustomerRelationshipsMember2025-07-012025-09-300000842633us-gaap:SellingGeneralAndAdministrativeExpenseus-gaap:CustomerRelationshipsMember2026-01-012026-09-300000842633us-gaap:SellingGeneralAndAdministrativeExpenseus-gaap:CustomerRelationshipsMember2025-01-012025-09-300000842633us-gaap:SegmentContinuingOperationsMember2026-07-012026-09-300000842633us-gaap:SegmentContinuingOperationsMember2025-07-012025-09-300000842633us-gaap:SegmentContinuingOperationsMember2026-01-012026-09-300000842633us-gaap:SegmentContinuingOperationsMember2025-01-012025-09-300000842633trs:OutOfPeriodAdjustmentMember2026-07-012026-09-300000842633us-gaap:LandAndLandImprovementsMember2026-09-300000842633us-gaap:LandAndLandImprovementsMember2025-12-310000842633us-gaap:BuildingMember2026-09-300000842633us-gaap:BuildingMember2025-12-310000842633us-gaap:MachineryAndEquipmentMember2026-09-300000842633us-gaap:MachineryAndEquipmentMember2025-12-310000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:CostOfGoodsAndServicesSold2026-07-012026-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:CostOfGoodsAndServicesSold2025-07-012025-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:CostOfGoodsAndServicesSold2026-01-012026-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:CostOfGoodsAndServicesSold2025-01-012025-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-07-012026-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-07-012025-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-01-012026-09-300000842633us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-01-012025-09-300000842633trs:A4125SeniorUnsecuredNotesDue2029Member2026-09-300000842633trs:A4125SeniorUnsecuredNotesDue2029Member2025-12-310000842633trs:CreditAgreementMember2026-09-300000842633trs:CreditAgreementMember2025-12-310000842633us-gaap:SeniorNotesMembertrs:A4125SeniorUnsecuredNotesDue2029Member2026-09-300000842633us-gaap:SeniorNotesMembertrs:A4125SeniorUnsecuredNotesDue2029Member2026-07-012026-09-300000842633us-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodFourMembertrs:A4125SeniorUnsecuredNotesDue2029Member2026-01-012026-09-300000842633us-gaap:RevolvingCreditFacilityMember2026-09-300000842633us-gaap:RevolvingCreditFacilityMember2026-09-300000842633us-gaap:RevolvingCreditFacilityMember2026-01-012026-09-300000842633us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2026-07-012026-09-300000842633us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2026-07-012026-09-300000842633us-gaap:LetterOfCreditMember2026-09-300000842633trs:RevolvingCreditAndTermLoanFacilitiesMember2026-09-300000842633us-gaap:RevolvingCreditFacilityMember2025-12-310000842633us-gaap:LetterOfCreditMember2025-12-310000842633us-gaap:RevolvingCreditFacilityMemberus-gaap:NonUsMember2026-09-300000842633us-gaap:RevolvingCreditFacilityMemberus-gaap:NonUsMember2025-12-310000842633trs:A4125SeniorUnsecuredNotesDue2029Memberus-gaap:FairValueInputsLevel2Member2026-09-300000842633trs:A4125SeniorUnsecuredNotesDue2029Memberus-gaap:FairValueInputsLevel2Member2025-12-310000842633us-gaap:RevolvingCreditFacilityMembertrs:CreditAgreementMember2026-09-300000842633us-gaap:RevolvingCreditFacilityMembertrs:CreditAgreementMemberus-gaap:FairValueInputsLevel2Member2026-09-300000842633us-gaap:RevolvingCreditFacilityMembertrs:CreditAgreementMember2025-12-310000842633us-gaap:RevolvingCreditFacilityMembertrs:CreditAgreementMemberus-gaap:FairValueInputsLevel2Member2025-12-310000842633us-gaap:DesignatedAsHedgingInstrumentMembertrs:June2024DerivativeDomainus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMembertrs:February2024DerivativeContractDateDomainus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-09-300000842633trs:February2024DerivativeContractDateDomainus-gaap:CrossCurrencyInterestRateContractMember2024-02-150000842633us-gaap:NondesignatedMembertrs:February2024DerivativeContractDateDomainus-gaap:ForeignExchangeContractMember2024-02-150000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesNoncurrentus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesNoncurrentus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-12-310000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-12-310000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-07-012026-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-07-012025-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-01-012026-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-01-012025-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMember2026-01-012026-09-300000842633us-gaap:DesignatedAsHedgingInstrumentMember2026-07-012026-09-300000842633us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2026-09-300000842633us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2026-07-012026-09-300000842633us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2025-07-012025-09-300000842633us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2026-01-012026-09-300000842633us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2025-01-012025-09-300000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2026-09-300000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-09-300000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-09-300000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-09-300000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2026-09-300000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-09-300000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-09-300000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-09-300000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310000842633us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310000842633us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310000842633us-gaap:AsbestosIssueMember2026-09-300000842633us-gaap:AsbestosIssueMember2025-12-310000842633us-gaap:AsbestosIssueMember2026-01-012026-09-300000842633us-gaap:AsbestosIssueMember2024-12-310000842633us-gaap:AsbestosIssueMember2026-01-012026-03-310000842633srt:MinimumMembertrs:PunitiveOnlyDamagesMemberus-gaap:AsbestosIssueMember2026-07-012026-09-300000842633srt:MinimumMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range1Member2026-01-012026-09-300000842633srt:MaximumMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range1Member2026-01-012026-09-300000842633srt:MinimumMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range2Member2026-01-012026-09-300000842633srt:MaximumMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range2Member2026-01-012026-09-300000842633srt:MinimumMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range3Member2026-01-012026-09-300000842633us-gaap:PendingLitigationMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range1Member2026-09-300000842633us-gaap:PendingLitigationMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range2Member2026-09-300000842633us-gaap:PendingLitigationMembertrs:CompensatoryOnlyDamagesMemberus-gaap:AsbestosIssueMembertrs:Range3Member2026-09-300000842633us-gaap:AsbestosIssueMember1991-01-012026-09-300000842633srt:MinimumMemberus-gaap:AsbestosIssueMember2025-09-300000842633srt:MaximumMemberus-gaap:AsbestosIssueMember2025-09-3000008426332025-10-012025-12-310000842633us-gaap:AsbestosIssueMember2025-01-012025-09-300000842633us-gaap:AsbestosIssueMember2025-09-300000842633us-gaap:EnvironmentalIssueMember2026-09-300000842633us-gaap:EnvironmentalIssueMember2025-12-310000842633trs:PackagingReportableSegmentMember2026-07-012026-09-300000842633trs:SpecialtyProductsReportableSegmentMember2026-07-012026-09-300000842633us-gaap:CorporateMember2026-07-012026-09-300000842633trs:PackagingReportableSegmentMember2025-07-012025-09-300000842633trs:SpecialtyProductsReportableSegmentMember2025-07-012025-09-300000842633us-gaap:CorporateMember2025-07-012025-09-300000842633us-gaap:CorporateMember2026-01-012026-09-300000842633trs:PackagingReportableSegmentMember2025-01-012025-09-300000842633trs:SpecialtyProductsReportableSegmentMember2025-01-012025-09-300000842633us-gaap:CorporateMember2025-01-012025-09-300000842633us-gaap:CorporateMember2026-09-300000842633us-gaap:CorporateMember2025-12-310000842633us-gaap:SegmentContinuingOperationsMember2026-09-300000842633us-gaap:SegmentContinuingOperationsMember2025-12-310000842633us-gaap:EmployeeStockOptionMember2026-01-012026-09-300000842633us-gaap:EmployeeStockOptionMember2026-09-300000842633us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-07-012026-09-300000842633us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-01-012026-09-300000842633us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-07-012025-09-300000842633us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-01-012025-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:Plan1Member2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:Plan3Member2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:Plan7Member2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:DividendEquivalentMember2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:Plan8Member2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:A3YearEpsCagrMetricMembertrs:Plan8Membersrt:MaximumMember2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:CashReturnOnNetAssetsMetricMembertrs:Plan8Membersrt:MaximumMember2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:TotalshareholderreturnmetricMembertrs:Plan8Membersrt:MinimumMember2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMembertrs:TotalshareholderreturnmetricMembertrs:Plan8Membersrt:MaximumMember2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMember2025-12-310000842633us-gaap:RestrictedStockUnitsRSUMember2026-09-300000842633us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-07-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingGeneralAndAdministrativeExpense2026-01-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-07-012025-09-300000842633us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingGeneralAndAdministrativeExpense2025-01-012025-09-300000842633us-gaap:RestrictedStockUnitsRSUMember2026-07-012026-09-300000842633us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-300000842633us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300000842633us-gaap:EmployeeStockOptionMember2026-07-012026-09-300000842633us-gaap:EmployeeStockOptionMember2025-07-012025-09-300000842633us-gaap:EmployeeStockOptionMember2025-01-012025-09-300000842633trs:A10b51sharerepurchaseprogramMember2026-02-260000842633trs:A10b51sharerepurchaseprogramMember2025-12-310000842633trs:A10b51sharerepurchaseprogramMember2026-07-012026-09-300000842633trs:A10b51sharerepurchaseprogramMember2026-01-012026-09-300000842633trs:A10b51sharerepurchaseprogramMember2025-07-012025-09-300000842633trs:A10b51sharerepurchaseprogramMember2025-01-012025-09-300000842633trs:A10b51sharerepurchaseprogramMember2026-09-300000842633us-gaap:PensionPlansDefinedBenefitMember2026-07-012026-09-300000842633us-gaap:PensionPlansDefinedBenefitMember2025-07-012025-09-300000842633us-gaap:PensionPlansDefinedBenefitMember2026-01-012026-09-300000842633us-gaap:PensionPlansDefinedBenefitMember2025-01-012025-09-300000842633us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:PensionPlansDefinedBenefitMember2026-01-012026-09-300000842633us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:PensionPlansDefinedBenefitMember2025-07-012025-09-300000842633us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-09-300000842633us-gaap:PensionPlansDefinedBenefitMember2026-09-300000842633us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-12-310000842633trs:AccumulatedNetGainLossfromHedgesAttributabletoParentMember2025-12-310000842633us-gaap:AccumulatedTranslationAdjustmentMember2025-12-310000842633us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-01-012026-09-300000842633trs:AccumulatedNetGainLossfromHedgesAttributabletoParentMember2026-01-012026-09-300000842633us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-09-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-09-300000842633us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-09-300000842633trs:AccumulatedNetGainLossfromHedgesAttributabletoParentMember2026-09-300000842633us-gaap:AccumulatedTranslationAdjustmentMember2026-09-300000842633us-gaap:CrossCurrencyInterestRateContractMember2026-01-012026-09-300000842633us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000842633trs:AccumulatedNetGainLossfromHedgesAttributabletoParentMember2024-12-310000842633us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000842633us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-300000842633trs:AccumulatedNetGainLossfromHedgesAttributabletoParentMember2025-01-012025-09-300000842633us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-300000842633us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-300000842633us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-09-300000842633trs:AccumulatedNetGainLossfromHedgesAttributabletoParentMember2025-09-300000842633us-gaap:AccumulatedTranslationAdjustmentMember2025-09-300000842633us-gaap:CrossCurrencyInterestRateContractMember2025-01-012025-09-300000842633us-gaap:ForeignCountryMember2026-07-012026-09-300000842633us-gaap:ForeignCountryMember2026-01-012026-09-300000842633trs:ProductionTaxCreditsMember2026-07-012026-09-300000842633us-gaap:SubsequentEventMembertrs:O2026Q3DividendsMember2026-10-222026-10-220000842633us-gaap:SubsequentEventMembertrs:O2026Q3DividendsMember2026-10-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 10-Q
| | | | | | | | | | | |
| (Mark One) | | | |
☒ | | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| | | |
| For the Quarterly Period Ended | September 30, 2026 |
| Or |
☐ | | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| | | |
For the Transition Period from to . |
Commission file number 001-10716
TRIMAS CORPORATION
(Exact name of registrant as specified in its charter)
| | | | | | | | |
| Delaware | | 38-2687639 |
(State or other jurisdiction of incorporation or organization) | | (IRS Employer Identification No.) |
38505 Woodward Avenue, Suite 200
Bloomfield Hills, Michigan 48304
(Address of principal executive offices, including zip code)
(248) 631-5450
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading symbol(s) | Name of exchange on which registered |
| Common stock, $0.01 par value | TRS | The NASDAQ Stock Market LLC |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | |
| Large accelerated filer | ☒ | | Accelerated filer | ☐ |
| | | | |
| Non-accelerated filer | ☐ | | Smaller reporting company | ☐ |
| | | | |
| | | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 12, 2026, the number of outstanding shares of the Registrant's common stock, $0.01 par value, was 35,285,062 shares.
TriMas Corporation
Index
| | | | | | | | | | | | | | | | | |
Part I. | | Financial Information | |
| | | | | |
| | | | Forward-Looking Statements | 2 |
| | | | | |
| | Item 1. | | Consolidated Financial Statements | 3 |
| | | | | |
| | | | Consolidated Balance Sheet as of September 30, 2026 and December 31, 2025 | 3 |
| | | | | |
| | | | Consolidated Statement of Income for the Three and Nine Months Ended September 30, 2026 and 2025 | 4 |
| | | | | |
| | | | Consolidated Statement of Comprehensive Income for the Three and Nine Months Ended September 30, 2026 and 2025 | 5 |
| | | | | |
| | | | Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 | 6 |
| | | | | |
| | | | Consolidated Statement of Shareholders' Equity for the Nine Months Ended September 30, 2026 and 2025 | 7 |
| | | | | |
| | | | Notes to Consolidated Financial Statements | 9 |
| | | | | |
| | Item 2. | | Management's Discussion and Analysis of Financial Condition and Results of Operations | 30 |
| | | | | |
| | Item 3. | | Quantitative and Qualitative Disclosures about Market Risk | 46 |
| | | | | |
| | Item 4. | | Controls and Procedures | 46 |
| | | | | |
Part II. | | Other Information | |
| | | | | |
| | Item 1. | | Legal Proceedings | 47 |
| | | | | |
| | Item 1A. | | Risk Factors | 47 |
| | | | | |
| | Item 2. | | Unregistered Sales of Equity Securities and Use of Proceeds | 47 |
| | | | | |
| | Item 3. | | Defaults Upon Senior Securities | 47 |
| | | | | |
| | Item 4. | | Mine Safety Disclosures | 47 |
| | | | | |
| | Item 5. | | Other Information | 47 |
| | | | | |
| | Item 6. | | Exhibits | 49 |
| | | | | |
| | Signatures | 50 |
Forward-Looking Statements
This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about our financial condition, results of operations and business. These forward-looking statements can be identified by the use of forward-looking words, such as “may,” “could,” “should,” “estimate,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “target,” “plan” or other comparable words, or by discussions of strategy that may involve risks and uncertainties.
These forward-looking statements are subject to numerous assumptions, risks and uncertainties which could materially affect our business, financial condition or future results including, but not limited to: general economic and currency conditions; competitive factors; market demand; our ability to realize our business strategies; government and regulatory actions, including, without limitation, the impact of current and future tariffs and reciprocal tariffs, quotas and surcharges, as well as climate change legislation and other environmental regulations; our ability to identify attractive acquisition candidates, successfully integrate acquired operations or realize the intended benefits of such acquisitions; our ability to recognize the benefits of and effectively deploy the net proceeds from the sale of our Aerospace segment; pressures on our supply chain, including the price and availability of raw materials, the impacts of geopolitical conflicts, and inflationary pressures on raw material and energy costs, and customers; the performance of our subcontractors and suppliers; risks and uncertainties associated with intangible assets, including goodwill or other intangible asset impairment charges; risks associated with a concentrated customer base; information technology and other cyber-related risks; risks related to our international operations; changes to fiscal and tax policies; intellectual property factors; uncertainties associated with our ability to meet customers’ and suppliers’ sustainability and environmental, social and governance ("ESG") goals and achieve our sustainability and ESG goals in alignment with our own announced targets; litigation; contingent liabilities relating to acquisition and disposition activities; interest rate volatility; our leverage; liabilities imposed by our debt instruments; labor disputes and shortages; the disruption of operations from catastrophic or extraordinary events, including, but not limited to, natural disasters, geopolitical conflicts and public health crises; the amount and timing of future dividends and/or share repurchases, which remain subject to Board approval and depend on market and other conditions; our future prospects; and other risks that are discussed in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, and elsewhere in this report. The risks described in our Annual Report on Form 10-K and elsewhere in this report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deemed to be immaterial also may materially adversely affect our business, financial position and results of operations or cash flows.
The cautionary statements set forth above should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. We caution readers not to place undue reliance on the statements, which speak only as of the date of this report. We do not undertake any obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statement to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by law.
We disclose important factors that could cause our actual results to differ materially from our expectations implied by our forward-looking statements under Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," in our Annual Report on Form 10-K for the year ended December 31, 2025 and elsewhere in this report. These cautionary statements qualify all forward-looking statements attributed to us or persons acting on our behalf. When we indicate that an event, condition or circumstance could or would have an adverse effect on us, we mean to include effects upon our business, financial and other conditions, results of operations, prospects and ability to service our debt.
PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
TriMas Corporation
Consolidated Balance Sheet
(Dollars in thousands)
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| Assets | | (unaudited) | | |
| Current assets: | | | | |
| Cash and cash equivalents | | $ | 1,158,540 | | | $ | 30,020 | |
Receivables, net of reserves of $1.7 million and $1.3 million as of September 30, 2026 and December 31, 2025, respectively | | 150,200 | | | 111,270 | |
| Inventories | | 115,750 | | | 108,720 | |
| Prepaid expenses and other current assets | | 31,880 | | | 36,380 | |
| Current assets, discontinued operations | | — | | | 176,280 | |
| Total current assets | | 1,456,370 | | | 462,670 | |
| Property and equipment, net | | 238,690 | | | 247,510 | |
| Operating lease right-of-use assets | | 34,740 | | | 31,800 | |
| Goodwill | | 295,730 | | | 300,280 | |
| Other intangibles, net | | 71,460 | | | 76,550 | |
| Deferred income taxes | | 6,200 | | | 53,670 | |
| Other assets | | 43,720 | | | 45,430 | |
| Non-current assets, discontinued operations | | — | | | 267,170 | |
| Total assets | | $ | 2,146,910 | | | $ | 1,485,080 | |
| Liabilities and Shareholders' Equity | | | | |
| Current liabilities: | | | | |
| | | | |
| Accounts payable | | $ | 114,600 | | | $ | 72,280 | |
| Accrued liabilities | | 58,670 | | | 59,640 | |
| Lease liabilities, current portion | | 8,060 | | | 4,100 | |
| Current liabilities, discontinued operations | | — | | | 47,650 | |
| Total current liabilities | | 181,330 | | | 183,670 | |
| Long-term debt, net | | 397,140 | | | 469,170 | |
| | | | |
| Lease liabilities | | 31,150 | | | 31,810 | |
| Deferred income taxes | | 30,050 | | | 17,710 | |
| Other long-term liabilities | | 57,700 | | | 65,840 | |
| Non-current liabilities, discontinued operations | | — | | | 11,290 | |
| Total liabilities | | 697,370 | | | 779,490 | |
Preferred stock, $0.01 par: Authorized 100,000,000 shares; Issued and outstanding: None | | — | | | — | |
Common stock, $0.01 par: Authorized 400,000,000 shares; Issued and outstanding: 35,641,636 shares at September 30, 2026 and 37,630,206 shares at December 31, 2025 | | 360 | | | 380 | |
| Paid-in capital | | 525,020 | | | 577,810 | |
| Retained earnings | | 927,130 | | | 127,410 | |
| Accumulated other comprehensive income (loss) | | (2,970) | | | (10) | |
| Total shareholders' equity | | 1,449,540 | | | 705,590 | |
| Total liabilities and shareholders' equity | | $ | 2,146,910 | | | $ | 1,485,080 | |
The accompanying notes are an integral part of these consolidated financial statements.
TriMas Corporation
Consolidated Statement of Income
(Unaudited—dollars in thousands, except for per share amounts)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Net sales | | $ | 178,740 | | | $ | 166,020 | | | $ | 521,600 | | | $ | 490,230 | |
| Cost of sales | | (145,110) | | | (131,550) | | | (415,760) | | | (384,980) | |
| Gross profit | | 33,630 | | | 34,470 | | | 105,840 | | | 105,250 | |
| Selling, general and administrative expenses | | (24,820) | | | (29,640) | | | (79,310) | | | (91,150) | |
| Asbestos-related costs | | — | | | (8,030) | | | — | | | (8,030) | |
| Net gain (loss) on dispositions of assets | | (100) | | | 20 | | | (70) | | | 5,290 | |
| | | | | | | | |
| Operating profit (loss) | | 8,710 | | | (3,180) | | | 26,460 | | | 11,360 | |
| Other expense, net: | | | | | | | | |
| Interest expense | | (4,140) | | | (4,360) | | | (13,500) | | | (13,430) | |
| | | | | | | | |
| Other income, net | | 9,920 | | | 1,080 | | | 22,140 | | | 1,310 | |
| Other income (expense), net | | 5,780 | | | (3,280) | | | 8,640 | | | (12,120) | |
| Income (loss) before income tax expense | | 14,490 | | | (6,460) | | | 35,100 | | | (760) | |
| Income tax (expense) benefit | | (3,020) | | | 1,570 | | | (8,120) | | | 220 | |
| Income (loss) from continuing operations | | 11,470 | | | (4,890) | | | 26,980 | | | (540) | |
| Income from discontinued operations, net of tax | | 5,900 | | | 14,190 | | | 804,590 | | | 38,980 | |
| | | | | | | | |
| | | | | | | | |
| Net income | | $ | 17,370 | | | $ | 9,300 | | | $ | 831,570 | | | $ | 38,440 | |
| Basic earnings (loss) per share: | | | | | | | | |
| Continuing operations | | $ | 0.32 | | | $ | (0.12) | | | $ | 0.74 | | | $ | (0.01) | |
| Discontinued operations | | 0.16 | | | 0.35 | | | 22.13 | | | 0.96 | |
| Net income per share | | $ | 0.48 | | | $ | 0.23 | | | $ | 22.87 | | | $ | 0.95 | |
| Weighted average common shares—basic | | 35,759,542 | | | 40,650,933 | | | 36,354,394 | | | 40,634,527 | |
| Diluted earnings (loss) per share: | | | | | | | | |
| Continuing operations | | $ | 0.32 | | | $ | (0.12) | | | $ | 0.74 | | | $ | (0.01) | |
| Discontinued operations | | 0.16 | | | 0.35 | | | 21.90 | | | 0.96 | |
| Net income per share | | $ | 0.48 | | | $ | 0.23 | | | $ | 22.64 | | | $ | 0.95 | |
| Weighted average common shares—diluted | | 36,063,656 | | | 40,650,933 | | | 36,738,157 | | | 40,634,527 | |
The accompanying notes are an integral part of these consolidated financial statements.
TriMas Corporation
Consolidated Statement of Comprehensive Income
(Unaudited—dollars in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Net income | | $ | 17,370 | | | $ | 9,300 | | | $ | 831,570 | | | $ | 38,440 | |
| Other comprehensive income (loss): | | | | | | | | |
| Defined benefit plans (Note 18) | | 20 | | | 10 | | | 1,650 | | | 30 | |
| Foreign currency translation | | (2,200) | | | (1,780) | | | (8,010) | | | 32,100 | |
| Derivative instruments (Note 11) | | 970 | | | 660 | | | 3,400 | | | (12,070) | |
| Total other comprehensive income (loss) | | (1,210) | | | (1,110) | | | (2,960) | | | 20,060 | |
| Total comprehensive income | | $ | 16,160 | | | $ | 8,190 | | | $ | 828,610 | | | $ | 58,500 | |
The accompanying notes are an integral part of these consolidated financial statements.
TriMas Corporation
Consolidated Statement of Cash Flows
(Unaudited—dollars in thousands)
| | | | | | | | | | | | | | |
| | Nine months ended September 30, |
| | 2026 | | 2025 |
| Cash Flows from Operating Activities: | | | | |
| Income (loss) from continuing operations | | $ | 26,980 | | | $ | (540) | |
| Income from discontinued operations | | 804,590 | | | 38,980 | |
| Net income | | 831,570 | | | 38,440 | |
| Adjustments to reconcile net income to net cash provided by (used for) operating activities, net of acquisition impact: | | | | |
| | | | |
| Net gain on dispositions of assets | | (1,040,140) | | | (5,120) | |
| Depreciation | | 27,160 | | | 29,770 | |
| Amortization of intangible assets | | 6,570 | | | 12,940 | |
| Amortization of debt issue costs | | 720 | | | 710 | |
| Deferred income taxes | | 4,840 | | | 4,140 | |
| Non-cash compensation expense | | 6,960 | | | 8,300 | |
| Provision for losses on accounts receivable | | 350 | | | (930) | |
| Change in asbestos liability estimate | | — | | | 8,030 | |
| | | | |
| | | | |
| | | | |
| | | | |
| Increase in receivables | | (46,320) | | | (18,280) | |
| Increase in inventories | | (15,360) | | | (8,390) | |
| Decrease in prepaid expenses and other assets | | 12,520 | | | 8,250 | |
| Increase in accounts payable and accrued liabilities | | 85,760 | | | 3,340 | |
| Other operating activities | | 740 | | | (5,270) | |
| | | | |
| | | | |
| Net cash provided by (used for) operating activities, net of acquisition impact | | (124,630) | | | 75,930 | |
| Cash Flows from Investing Activities: | | | | |
| Capital expenditures | | (20,160) | | | (43,650) | |
| Acquisition of business, net of cash acquired | | — | | | (37,730) | |
| | | | |
| | | | |
| Net proceeds from disposition of business, property and equipment | | 1,437,660 | | | 21,780 | |
| | | | |
| | | | |
| Net cash provided by (used for) investing activities | | 1,417,500 | | | (59,600) | |
| Cash Flows from Financing Activities: | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Proceeds from borrowings on revolving credit facilities | | 233,000 | | | 169,300 | |
| Repayments of borrowings on revolving credit facilities | | (305,730) | | | (164,770) | |
| | | | |
| Debt financing fees | | — | | | (1,260) | |
| | | | |
| | | | |
| | | | |
| Payments to purchase common stock | | (82,730) | | | (2,260) | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | (4,490) | | | (1,850) | |
| | | | |
| Dividends paid | | (4,400) | | | (4,950) | |
| Other financing activities | | — | | | 30 | |
| | | | |
| | | | |
| Net cash used for financing activities | | (164,350) | | | (5,760) | |
| Cash and Cash Equivalents: | | | | |
| Increase for the period | | 1,128,520 | | | 10,570 | |
| At beginning of period | | 30,020 | | | 23,070 | |
| At end of period | | $ | 1,158,540 | | | $ | 33,640 | |
| Supplemental disclosure of cash flow information: | | | | |
| Cash paid for interest | | $ | 10,180 | | | $ | 9,920 | |
| Cash paid for taxes | | $ | 132,470 | | | $ | 11,290 | |
| Non-cash property additions | | $ | 1,900 | | | $ | — | |
The accompanying notes are an integral part of these consolidated financial statements.
TriMas Corporation
Consolidated Statement of Shareholders' Equity
Nine Months Ended September 30, 2026 and 2025
(Unaudited—dollars in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Common Stock | | Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Total |
| Balances, December 31, 2025 | | $ | 380 | | | $ | 577,810 | | | $ | 127,410 | | | $ | (10) | | | $ | 705,590 | |
| Net income | | — | | | — | | | 800,830 | | | — | | | 800,830 | |
| Other comprehensive loss | | — | | | — | | | — | | | (200) | | | (200) | |
| | | | | | | | | | |
| Purchase of common stock | | (20) | | | (44,880) | | | (9,630) | | | — | | | (54,530) | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | — | | | (3,460) | | | — | | | — | | | (3,460) | |
| | | | | | | | | | |
| | | | | | | | | | |
| Non-cash compensation expense | | — | | | 3,070 | | | — | | | — | | | 3,070 | |
| Dividends declared | | — | | | — | | | (1,490) | | | — | | | (1,490) | |
| | | | | | | | | | |
| Balances, March 31, 2026 | | $ | 360 | | | $ | 532,540 | | | $ | 917,120 | | | $ | (210) | | | $ | 1,449,810 | |
| Net income | | — | | | — | | | 13,370 | | | — | | | 13,370 | |
| Other comprehensive loss | | — | | | — | | | — | | | (1,550) | | | (1,550) | |
| Purchase of common stock | | — | | | (6,940) | | | (11,990) | | | — | | | (18,930) | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | — | | | (970) | | | — | | | — | | | (970) | |
| | | | | | | | | | |
| | | | | | | | | | |
| Non-cash compensation expense | | — | | | 2,340 | | | — | | | — | | | 2,340 | |
| Dividends declared | | — | | | — | | | (1,460) | | | — | | | (1,460) | |
| Balances, June 30, 2026 | | $ | 360 | | | $ | 526,970 | | | $ | 917,040 | | | $ | (1,760) | | | $ | 1,442,610 | |
| Net income | | — | | | — | | | 17,370 | | | — | | | 17,370 | |
| Other comprehensive loss | | — | | | — | | | — | | | (1,210) | | | (1,210) | |
| Purchase of common stock | | — | | | (3,440) | | | (5,830) | | | — | | | (9,270) | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | — | | | (60) | | | — | | | — | | | (60) | |
| | | | | | | | | | |
| | | | | | | | | | |
| Non-cash compensation expense | | — | | | 1,550 | | | — | | | — | | | 1,550 | |
| Dividends declared | | — | | | — | | | (1,450) | | | — | | | (1,450) | |
| Balances, September 30, 2026 | | $ | 360 | | | $ | 525,020 | | | $ | 927,130 | | | $ | (2,970) | | | $ | 1,449,540 | |
The accompanying notes are an integral part of these consolidated financial statements.
TriMas Corporation
Consolidated Statement of Shareholders' Equity
Nine Months Ended September 30, 2026 and 2025
(Unaudited—dollars in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Common Stock | | Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Total |
| Balances, December 31, 2024 | | $ | 410 | | | $ | 663,770 | | | $ | 21,670 | | | $ | (18,550) | | | $ | 667,300 | |
| Net income | | — | | | — | | | 12,420 | | | — | | | 12,420 | |
| Other comprehensive income | | — | | | — | | | — | | | 7,690 | | | 7,690 | |
| | | | | | | | | | |
| Purchase of common stock | | — | | | (450) | | | (10) | | | — | | | (460) | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | — | | | (1,760) | | | — | | | — | | | (1,760) | |
| | | | | | | | | | |
| | | | | | | | | | |
| Non-cash compensation expense | | — | | | 2,990 | | | — | | | — | | | 2,990 | |
| Dividends declared | | — | | | — | | | (1,610) | | | — | | | (1,610) | |
| Balances, March 31, 2025 | | $ | 410 | | | $ | 664,550 | | | $ | 32,470 | | | $ | (10,860) | | | $ | 686,570 | |
| Net income | | — | | | — | | | 16,720 | | | — | | | 16,720 | |
| Other comprehensive income | | — | | | — | | | — | | | 13,480 | | | 13,480 | |
| Purchase of common stock | | — | | | (1,720) | | | (80) | | | — | | | (1,800) | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | — | | | (40) | | | — | | | — | | | (40) | |
| Non-cash compensation expense | | — | | | 2,010 | | | — | | | — | | | 2,010 | |
| Dividends declared | | — | | | — | | | (1,670) | | | — | | | (1,670) | |
| Balances, June 30, 2025 | | $ | 410 | | | $ | 664,800 | | | $ | 47,440 | | | $ | 2,620 | | | $ | 715,270 | |
| Net income | | — | | | — | | | 9,300 | | | — | | | 9,300 | |
| Other comprehensive loss | | — | | | — | | | — | | | (1,110) | | | (1,110) | |
| | | | | | | | | | |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes | | — | | | (50) | | | — | | | — | | | (50) | |
| | | | | | | | | | |
| | | | | | | | | | |
| Non-cash compensation expense | | — | | | 3,300 | | | — | | | — | | | 3,300 | |
| Dividends declared | | — | | | — | | | (1,670) | | | — | | | (1,670) | |
| Balances, September 30, 2025 | | $ | 410 | | | $ | 668,050 | | | $ | 55,070 | | | $ | 1,510 | | | $ | 725,040 | |
The accompanying notes are an integral part of these consolidated financial statements.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. Basis of Presentation
TriMas Corporation ("TriMas" or the "Company"), and its consolidated subsidiaries, designs, engineers and manufactures innovative products under leading brand names for customers primarily in the consumer products and industrial markets.
The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries and, in the opinion of management, contain all adjustments, including adjustments of a normal and recurring nature, necessary for a fair presentation of financial position and results of operations. The preparation of financial statements requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities. Actual results may differ from such estimates and assumptions due to risks and uncertainties, including uncertainty and volatility in the current economic environment due to input cost inflation, supply chain disruptions, and shortages in global markets for commodities, logistics and labor. To the extent there are differences between these estimates and actual results, the Company's consolidated financial statements may be materially affected. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes.
Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company's 2025 Annual Report on Form 10-K.
On March 16, 2026, the Company completed the previously announced sale of its Aerospace segment ("Aerospace"), a transaction entered into with an affiliate of Tinicum L.P., and funds managed by Blackstone, Inc. on November 4, 2025. Aerospace was sold for approximately $1,457.1 million in cash, subject to customary post-closing adjustments, which the Company finalized during the third quarter of 2026. The financial results of Aerospace were previously reported within the Company's Aerospace reportable segment, and are presented as discontinued operations for all periods presented in the financial statements attached hereto.
2. New Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In September 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2025-06, "Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software" ("ASU 2025-06"), which modernizes the accounting for software costs by removing references to prescriptive and sequential software development stages. Under ASU 2025-06 an entity is required to start capitalizing software costs when management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2027, with early adoption permitted. The Company adopted ASU 2025-06 in the first quarter of 2026 with no material impact on its consolidated financial statements.
In July 2025, the FASB issued ASU 2025-05, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets" ("ASU 2025-05"), which provides a practical expedient that assumes current conditions as of the balance sheet date remain unchanged when developing forecasts for estimating expected credit losses. Under ASU 2025-05, an entity is required to disclose that it has elected to use the practical expedient and the election should be applied prospectively. ASU 2025-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2025, with early adoption permitted. The Company adopted ASU 2025-05 in the first quarter of 2026 with no material impact on its consolidated financial statements.
Recently Issued Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses" ("ASU 2024-03"), which requires disclosures, in the notes to the financial statements, about the types of expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is in the process of assessing the impact of adoption on its consolidated financial statements.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
3. Discontinued Operations
On March 16, 2026, the Company completed the previously announced sale of Aerospace to an affiliate of Tinicum L.P., and funds managed by Blackstone, Inc., pursuant to an Equity Purchase Agreement dated as of November 4, 2025 (the "Purchase Agreement"), for a purchase price of approximately $1,457.1 million, subject to certain adjustments as set forth in the Purchase Agreement, which the Company finalized during the third quarter of 2026.
The Company recognized net proceeds of $1,242.5 million, which represents the purchase price, less estimated tax payments of approximately $194.5 million, and transaction costs of $20.2 million. The Company recorded a pre-tax gain on the sale of $1,040.2 million. The Company also recorded a $5.7 million tax benefit in discontinued operations during the three months ended September 30, 2026. See Note 20, "Income Taxes," for further details. The Company's liability for unpaid estimated tax payments is included in accounts payable in the accompanying consolidated balance sheet.
As of September 30, 2026, the Company’s net cash proceeds were invested in liquid instruments, including U.S. Treasury Bills, U.S. Treasury‑backed money market funds, and cash deposits with high‑credit‑quality financial institutions designated as Globally Systemically Important Banks. These investments earn interest at an average rate of 3.9%, and qualify as permitted investments under the Company’s credit agreement. The Company intends to maintain these investments until they are deployed for organic growth initiatives, strategically aligned acquisition opportunities, share repurchases, or a combination thereof.
The historical results for Aerospace are reported in the accompanying consolidated statement of income as a discontinued operation and the assets and liabilities have been retrospectively reclassified to assets and liabilities of discontinued operations in the accompanying consolidated balance sheet.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The carrying value of the assets and liabilities held in discontinued operations were as follows (dollars in thousands):
| | | | | | | | |
| | December 31, 2025 |
| Assets | | |
| Current assets: | | |
| | |
| Receivables, net | | $ | 60,460 | |
| Inventories | | 113,950 | |
| | |
| Prepaid expenses and other current assets | | 1,870 | |
| Total current assets | | 176,280 | |
| Property and equipment, net | | 90,780 | |
| Operating lease right-of-use assets | | 10,360 | |
| Goodwill | | 86,960 | |
| Other intangibles, net | | 77,530 | |
| Other assets | | 1,540 | |
| Total assets | | $ | 443,450 | |
| | |
| Liabilities and Shareholders' Equity | | |
| Current liabilities: | | |
| | |
| Accounts payable | | $ | 16,370 |
| Accrued liabilities | | 25,000 |
| Lease liabilities, current portion | | 6,280 |
| Total current liabilities | | 47,650 | |
| | |
| Lease liabilities | | 4,540 |
| Deferred income taxes | | 6,160 |
| Other long-term liabilities | | 590 |
| Total liabilities | | $ | 58,940 | |
Results of discontinued operations are summarized as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Net sales | | $ | — | | | $ | 103,240 | | | $ | 83,920 | | | $ | 295,460 | |
| Cost of sales | | — | | | (71,800) | | | (59,850) | | | (208,050) | |
| Gross profit | | — | | | 31,440 | | | 24,070 | | | 87,410 | |
| Selling, general and administrative expenses | | — | | | (11,500) | | | (12,710) | | | (33,100) | |
| Net gain (loss) on dispositions of assets | | 200 | | | (170) | | | 1,040,200 | | | (170) | |
| | | | | | | | |
| Operating profit | | 200 | | | 19,770 | | | 1,051,560 | | | 54,140 | |
| | | | | | | | |
| | | | | | | | |
| Other expense, net | | — | | | (1,180) | | | (2,180) | | | (1,740) | |
| Income from discontinued operations, before income taxes | | 200 | | | 18,590 | | | 1,049,380 | | | 52,400 | |
| Income tax (expense) benefit | | 5,700 | | | (4,400) | | | (244,790) | | | (13,420) | |
| Income from discontinued operations, net of tax | | $ | 5,900 | | | $ | 14,190 | | | $ | 804,590 | | | $ | 38,980 | |
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The depreciation, amortization, capital expenditures, and significant cash flow items of the discontinued operations were as follows (dollars in thousands):
| | | | | | | | | | | | | | |
| | Nine months ended September 30, |
| | 2026 | | 2025 |
| Cash flows from discontinued operating activities: | | | | |
| Depreciation | | $ | 2,200 | | | $ | 6,040 | |
| Amortization of intangible assets | | 2,690 | | | 7,960 | |
| Net (gain) loss on dispositions of assets | | (1,040,200) | | | 170 | |
| Non-cash compensation expense | | (90) | | | 1,270 | |
| | | | |
| | | | |
| | | | |
| Cash flows from discontinued investing activities: | | | | |
| Capital expenditures | | $ | (2,820) | | | $ | (12,160) | |
| | | | |
| Acquisition of businesses, net of cash acquired | | — | | | (37,730) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
4. Revenue
The following table presents the Company’s disaggregated net sales by primary market served (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| Customer Markets | | 2026 | | 2025 | | 2026 | | 2025 |
| Consumer Products | | $ | 121,470 | | | $ | 110,480 | | | $ | 352,020 | | | $ | 330,980 | |
| | | | | | | | |
| Industrial | | 57,270 | | | 55,540 | | | 169,580 | | | 159,250 | |
| Total net sales | | $ | 178,740 | | | $ | 166,020 | | | $ | 521,600 | | | $ | 490,230 | |
The Company’s Packaging segment earns revenues from the consumer products (comprised of the beauty and personal care, food and beverage, home care, pharmaceutical, nutraceutical and medical submarkets) and industrial markets. The Specialty Products segment earns revenues from a variety of submarkets within the industrial market.
Contract Assets and Contract Liabilities
The Company has contract assets and contract liabilities primarily related to in-process tooling projects for long-term supply arrangements with a contractual guarantee for reimbursement by the customer. Contract assets primarily consist of capitalized costs related to customer-owned tooling contracts, wherein the Company has not yet met performance obligations. Contract liabilities include deferred tooling revenue, where the performance obligation was not met. The performance obligation is satisfied and cost of goods sold is recognized and released from the balance sheet when control of the tooling is transferred to the customer.
The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (dollars in thousands):
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| Contract asset | | $ | 6,260 | | | $ | 8,010 | |
| Contract liabilities | | 7,450 | | | 11,610 | |
During the nine months ended September 30, 2026, the Company recognized $7.3 million of revenue that was recorded as a contract liability as of December 31, 2025. The remainder of the change in the contract liability balance was primarily due to additional deferrals from new billings.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
5. Realignment Actions
2026 Realignment Actions
During the nine months ended September 30, 2026, the Company incurred realignment charges in its Packaging segment and corporate office, primarily for severance, as well as related to the closure and consolidation of its Atkins, Arkansas facility into other locations. In connection with these actions, the Company recorded pre-tax realignment charges of $0.8 million and $7.0 million during the three and nine months ended September 30, 2026, respectively. Pre-tax realignment charges recorded during the three months ended September 30, 2026, consisted of $0.8 million of employee-related costs, all of which were recorded in selling, general and administrative expenses in the accompanying consolidated statement of income. Pre-tax realignment charges recorded during the nine months ended September 30, 2026, consisted of $5.1 million for employee-related costs, $1.4 million related to facility move and consolidation costs, and $0.5 million related to charges to accelerate the depreciation of certain fixed assets. For the nine months ended September 30, 2026, $1.9 million and $5.1 million of these charges were included in cost of sales and selling, general and administrative expenses, respectively, in the accompanying consolidated statement of income.
2025 Realignment Actions
During the three and nine months ended September 30, 2025, the Company recorded $0.4 million and $4.9 million, respectively, of realignment costs related to actions to reorganize its corporate office, primarily for severance and consulting costs, including $1.5 million of non-cash compensation expense during the nine months ended September 30, 2025. These charges were included in selling, general and administrative expenses in the accompanying consolidated statement of income.
6. Acquisitions and Sale of Business
Acquisitions
On February 17, 2025, the Company acquired the aerospace business ("GMT Aerospace") of GMT Gummi-Metall-Technik GmbH for a purchase price of $37.7 million. The fair value of assets acquired and liabilities assumed included $15.5 million of goodwill, $4.6 million of intangible assets, $0.2 million of property and equipment, and $17.4 million of net working capital. GMT Aerospace was part of the Aerospace segment, which has been presented as discontinued operations for all periods presented.
Sale of Business
On January 31, 2025, the Company completed the sale of its Arrow Engine business within the Specialty Products segment for net cash proceeds of $21.0 million. As a result, the Company recorded a pre-tax gain of $0.1 million and $5.4 million for the three and nine months ended September 30, 2025, respectively.
7. Goodwill and Other Intangible Assets
Goodwill
Changes in the carrying amount of goodwill for the nine months ended September 30, 2026 are summarized as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Packaging | | | | Specialty Products | | Total |
| Balance, December 31, 2025 | $ | 293,720 | | | | | $ | 6,560 | | | $ | 300,280 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Foreign currency translation and other | (4,550) | | | | | — | | | (4,550) | |
| Balance, September 30, 2026 | $ | 289,170 | | | | | $ | 6,560 | | | $ | 295,730 | |
| | | | | | | |
| Accumulated impairment losses at September 30, 2026 | $ | 58,660 | | | | | $ | — | | | $ | 58,660 | |
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Other Intangible Assets
The Company amortizes its other intangible assets over periods ranging from one to 30 years. The gross carrying amounts and accumulated amortization of the Company's other intangibles are summarized below (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | As of September 30, 2026 | | As of December 31, 2025 |
| Intangible Category by Useful Life | | Gross Carrying Amount | | Accumulated Amortization | | Gross Carrying Amount | | Accumulated Amortization |
| Finite-lived intangible assets: | | | | | | | | |
Customer relationships, 5 – 12 years | | $ | 97,690 | | | $ | (74,170) | | | $ | 99,270 | | | $ | (71,810) | |
Customer relationships, 15 – 25 years | | 39,280 | | | (39,280) | | | 39,280 | | | (39,280) | |
| Total customer relationships | | 136,970 | | | (113,450) | | | 138,550 | | | (111,090) | |
Technology and other, 1 – 15 years | | 13,520 | | | (12,300) | | | 13,630 | | | (12,140) | |
Technology and other, 17 – 30 years | | 41,600 | | | (40,000) | | | 41,600 | | | (39,740) | |
| Total technology and other | | 55,120 | | | (52,300) | | | 55,230 | | | (51,880) | |
| Indefinite-lived intangible assets: | | | | | | | | |
| Trademark/Trade names | | 45,120 | | | — | | | 45,740 | | | — | |
| Total other intangible assets | | $ | 237,210 | | | $ | (165,750) | | | $ | 239,520 | | | $ | (162,970) | |
Amortization expense related to intangible assets as included in the accompanying consolidated statement of income is summarized as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Technology and other, included in cost of sales | | $ | 180 | | | $ | 190 | | | $ | 550 | | | $ | 550 | |
| Customer relationships, included in selling, general and administrative expenses | | 1,080 | | | 1,520 | | | 3,330 | | | 4,430 | |
| Total amortization expense | | $ | 1,260 | | | $ | 1,710 | | | $ | 3,880 | | | $ | 4,980 | |
8. Inventories
Inventories consist of the following components (dollars in thousands):
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| Finished goods | | $ | 44,260 | | | $ | 45,540 | |
| Work in process | | 24,560 | | | 24,130 | |
| Raw materials | | 46,930 | | | 39,050 | |
| Total inventories | | $ | 115,750 | | | $ | 108,720 | |
During the third quarter of 2026, management determined that the inventory value at its Norris Cylinder subsidiary was overstated by $1.6 million as a result of quantity errors that began in the fourth quarter of 2025 and continued over the first two quarters of 2026. The Company recorded an out-of-period charge to cost of sales, and a corresponding reduction in the value of raw material inventory, during the third quarter of 2026 for $1.6 million. The Company evaluated the materiality of this misstatement based on an analysis of quantitative and qualitative factors and concluded it was not material to the current period or any previously issued financial statements.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
9. Property and Equipment, Net
Property and equipment consists of the following components (dollars in thousands):
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| Land and land improvements | | $ | 7,120 | | | $ | 7,290 | |
| Buildings | | 67,260 | | | 66,590 | |
| Machinery and equipment | | 457,690 | | | 450,960 | |
| | 532,070 | | | 524,840 | |
| Less: Accumulated depreciation | | 293,380 | | | 277,330 | |
| Property and equipment, net | | $ | 238,690 | | | $ | 247,510 | |
Depreciation expense as included in the accompanying consolidated statement of income is as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Depreciation expense, included in cost of sales | | $ | 7,780 | | | $ | 7,910 | | | $ | 24,290 | | | $ | 23,020 | |
| Depreciation expense, included in selling, general and administrative expenses | | 230 | | | 230 | | | 670 | | | 710 | |
| Total depreciation expense | | $ | 8,010 | | | $ | 8,140 | | | $ | 24,960 | | | $ | 23,730 | |
10. Long-term Debt
The Company's long-term debt consists of the following (dollars in thousands):
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| 4.125% Senior Notes due April 2029 | | $ | 400,000 | | | $ | 400,000 | |
| | | | |
| Credit Agreement | | — | | | 72,790 | |
| | | | |
| Debt issuance costs | | (2,860) | | | (3,620) | |
| | | | |
| | | | |
| Long-term debt, net | | $ | 397,140 | | | $ | 469,170 | |
Senior Notes
In March 2021, the Company issued $400.0 million aggregate principal amount of 4.125% senior notes due April 15, 2029 ("Senior Notes") at par value in a private placement under Rule 144A of the Securities Act of 1933, as amended ("Securities Act"). The Senior Notes accrue interest at a rate of 4.125% per annum, payable semi-annually in arrears on April 15 and October 15. The payment of principal and interest is jointly and severally guaranteed, on a senior unsecured basis, by certain subsidiaries of the Company. The Senior Notes are pari passu in right of payment with all existing and future senior indebtedness and effectively subordinated to all existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness.
The Company may redeem all or part of the Senior Notes at par (100% of principal amount), plus accrued and unpaid interest, if any, to the redemption date.
Credit Agreement
In March 2025, the Company amended its existing credit agreement ("Credit Agreement") to extend the maturity date. The Company incurred fees and expenses of $1.3 million during the nine months ended September 30, 2025 related to the amendment, all of which was capitalized as debt issuance costs. The Company also recorded $0.1 million of non-cash expense related to the write-off of previously capitalized deferred financing fees in the nine months ended September 30, 2025. The Credit Agreement consists of a $250.0 million senior secured revolving credit facility, which permits borrowings denominated in specific foreign currencies, subject to a $125.0 million sub limit, maturing on March 31, 2030.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The Credit Agreement is subject to benchmark interest rates determined based on the currency denomination of borrowings, with British pound sterling borrowings subject to the Sterling Overnight Index Average, Euro borrowings to the Euro InterBank Offered Rate and U.S. dollar borrowings subject to the Secured Overnight Financing Rate, each plus a spread that ranges from 1.375% to 2.00% based upon the leverage ratio, as defined, as of the most recent determination date. The Company's revolving credit facility allows for the issuance of letters of credit, not to exceed $40.0 million in aggregate.
The Credit Agreement also provides incremental revolving credit facility commitments in an amount not to exceed the greater of $200.0 million and an amount such that, after giving effect to such incremental commitments and the incurrence of any other indebtedness substantially simultaneously with the making of such commitments, the senior secured net leverage ratio, as defined, is no greater than 3.00 to 1.00. The terms and conditions of any incremental revolving credit facility commitments must be no more favorable than the existing credit facility.
At September 30, 2026, the Company had no amounts outstanding under its revolving credit facility and had $243.8 million available after giving effect to $6.2 million of letters of credit issued and outstanding. At December 31, 2025, the Company had $72.8 million outstanding under its revolving credit facility and had $171.2 million available after giving effect to $6.0 million of letters of credit issued and outstanding. After consideration of leverage restrictions contained in the Credit Agreement, as of September 30, 2026, the Company had $203.0 million of borrowing capacity available for general corporate purposes. The Company's borrowing capacity was not reduced by leverage restrictions contained in the Credit Agreement as of December 31, 2025.
The debt under the Credit Agreement is an obligation of the Company and certain of its domestic subsidiaries and is secured by substantially all of the assets of such parties. Borrowings under the $125.0 million (equivalent) foreign currency sub limit of the $250.0 million senior secured revolving credit facility are secured by a cross-guarantee amongst, and a pledge of the assets of, the foreign subsidiary borrowers that are a party to the agreement. The Credit Agreement also contains various negative and affirmative covenants and other requirements affecting the Company and its subsidiaries, including the ability, subject to certain exceptions and limitations, to incur debt, liens, mergers, investments, loans, advances, guarantee obligations, acquisitions, asset dispositions, sale-leaseback transactions, hedging agreements, dividends and other restricted payments, transactions with affiliates, restrictive agreements and amendments to charters, bylaws, and other material documents. The terms of the Credit Agreement also require the Company and its restricted subsidiaries to meet certain restrictive financial covenants and ratios computed quarterly, including a maximum total net leverage ratio (total consolidated indebtedness plus outstanding amounts under any accounts receivable securitization facility, less the aggregate amount of certain unrestricted cash and unrestricted permitted investments, as defined, over consolidated EBITDA, as defined) and a minimum interest expense coverage ratio (consolidated EBITDA, as defined, over the sum of consolidated cash interest expense, as defined, and preferred dividends, as defined). In December 2025 and March 2026, the Company amended the Credit Agreement to update certain definitions used in ratio and indebtedness calculations due to the sale of the Aerospace segment. At September 30, 2026, the Company was in compliance with its financial covenants contained in the Credit Agreement.
Other Revolving Loan Facility
In May 2021, the Company, through one of its non-U.S. subsidiaries, entered into a revolving loan facility with a borrowing capacity of $4 million. The facility is guaranteed by TriMas Corporation. There were no borrowings outstanding on this loan facility as of September 30, 2026, or December 31, 2025.
Fair Value of Debt
The valuations of the Senior Notes and revolving credit facility were determined based on Level 2 inputs under the fair value hierarchy, as defined. The carrying amounts and fair values were as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| | Carrying Amount | | Fair Value | | Carrying Amount | | Fair Value |
| 4.125% Senior Notes due April 2029 | | $ | 400,000 | | | $ | 376,000 | | | $ | 400,000 | | | $ | 387,000 | |
| | | | | | | | |
| Revolving credit facility | | — | | | — | | | 72,790 | | | 72,790 | |
| | | | | | | | |
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
11. Derivative Instruments
Derivatives Designated as Hedging Instruments
The Company uses cross-currency swap contracts to hedge its net investment in Euro-denominated assets against future volatility in the exchange rate between the U.S. dollar and the Euro. By doing so, the Company synthetically converts a portion of its U.S. dollar-based long-term debt into Euro-denominated long-term debt.
The Company entered into a cross-currency swap agreement effective as of June 27, 2024, with a notional amount of $75.0 million and a contract period end date of October 15, 2027. Under the terms of the agreement, the Company is to receive net interest payments at a fixed rate of approximately 1.43% of the notional amount. At inception, the cross-currency swap was designated as a net investment hedge.
In February 2024, the Company entered into a cross-currency swap agreement effective as of April 15, 2024, with a notional amount of $75.0 million and a contract period end date of April 15, 2029. Under the terms of the agreement, the Company is to receive net interest payments at a fixed rate of approximately 1.06% of the notional amount. At inception, the cross-currency swap was designated as a net investment hedge. At designation, the cross-currency swap had an inception date non-zero fair value equal to a $4.9 million liability, which offset the inception date non-zero fair value of a $75.0 million foreign currency exchange forward contract entered into on the same date.
As of September 30, 2026 and December 31, 2025, the fair value carrying amount of the Company's derivatives designated as hedging instruments are recorded as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | |
| | | | Asset / (Liability) Derivatives |
| Derivatives Designated as Hedging Instruments | | Balance Sheet Caption | | September 30, 2026 | | December 31, 2025 |
| Net Investment Hedges | | | | | | |
| | | | | | |
| | | | | | |
| Cross-currency swaps | | Other long-term liabilities | | $ | (13,710) | | | $ | (18,270) | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
The following table summarizes the income recognized in accumulated other comprehensive income (loss) ("AOCI") on derivative contracts designated as hedging instruments as of September 30, 2026 and December 31, 2025, and the amounts reclassified from AOCI into earnings for the nine months ended September 30, 2026 and 2025 (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Amount of Income Recognized in AOCI on Derivatives (Effective Portion, net of tax) | | | | Amount of Income (Loss) Reclassified from AOCI into Earnings |
| As of September 30, 2026 | | As of December 31, 2025 | | Location of Income (Loss) Reclassified from AOCI into Earnings (Effective Portion) | | Three months ended September 30, | | Nine months ended September 30, |
| | | | 2026 | | 2025 | | 2026 | | 2025 |
| Net Investment Hedges | | | | | | | | | | | | | |
| Cross-currency swaps | $ | 8,120 | | | $ | 4,720 | | | Other income (expense), net | | $ | — | | | $ | — | | | $ | — | | | $ | — | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Over the next 12 months, the Company does not expect to reclassify any pre-tax deferred amounts from AOCI into earnings.
Derivatives Not Designated as Hedging Instruments
As of September 30, 2026, the Company was party to foreign currency exchange forward contracts to economically hedge changes in foreign currency rates with notional amounts of $120.6 million. The Company uses foreign exchange contracts to mitigate the risk associated with fluctuations in currency rates impacting cash flows related to certain of its receivables, payables and intercompany transactions denominated in foreign currencies. The foreign exchange contracts primarily mitigate currency exposures between the Euro and British pound, U.S. dollar and Mexican peso, U.S. dollar and Chinese yuan, as well as between the Brazilian Real and the British pound, and have various settlement dates through December 2026. These contracts are not designated as hedge instruments; therefore, gains and losses on these contracts are recognized each period directly into the consolidated statement of income.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The following table summarizes the effects of derivatives not designated as hedging instruments on the Company's consolidated statement of income (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Location of Income (Loss) Recognized in Earnings on Derivatives | | Amount of Income (Loss) Recognized in Earnings on Derivatives |
| | | Three months ended September 30, | | Nine months ended September 30, |
| | | 2026 | | 2025 | | 2026 | | 2025 |
| Derivatives not designated as hedging instruments | | | | | | | | | | |
| Foreign exchange contracts | | Other income (expense), net | | $ | 590 | | | $ | (2,060) | | | $ | (230) | | | $ | (8,920) | |
| | | | | | | | | | |
Fair Value of Derivatives
The fair value of the Company's derivatives are estimated using an income approach based on valuation techniques to convert future amounts to a single, discounted amount. Estimates of the fair value of the Company's cross-currency swaps and foreign exchange contracts use observable inputs such as interest rate yield curves and forward currency exchange rates. Fair value measurements and the fair value hierarchy level for the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 are shown below (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Description | | Frequency | | Asset / (Liability) | | Quoted Prices in Active Markets for Identical Assets (Level 1) | | Significant Other Observable Inputs (Level 2) | | Significant Unobservable Inputs (Level 3) |
| September 30, 2026 | | | | | | | | | | |
| Cross-currency swaps | | Recurring | | $ | (13,710) | | | $ | — | | | $ | (13,710) | | | $ | — | |
| Foreign exchange contracts | | Recurring | | $ | 190 | | | $ | — | | | $ | 190 | | | $ | — | |
| December 31, 2025 | | | | | | | | | | |
| Cross-currency swaps | | Recurring | | $ | (18,270) | | | $ | — | | | $ | (18,270) | | | $ | — | |
| Foreign exchange contracts | | Recurring | | $ | 90 | | | $ | — | | | $ | 90 | | | $ | — | |
12. Leases
The majority of the Company's lease obligations are non-cancelable operating leases for certain equipment and facilities. The Company's finance leases are for certain equipment for its operations in The Netherlands. Leases with an initial term of 12 months or less are not recorded on the balance sheet; expense related to these leases is recognized on a straight-line basis over the lease term.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Supplemental balance sheet information related to the Company's leases are shown below (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | |
| | Balance Sheet Location | | September 30, 2026 | | December 31, 2025 |
| Assets | | | | | | |
| Operating leases | | Operating lease right-of-use assets | | $ | 34,740 | | | $ | 31,800 | |
| Finance leases | | Property and equipment, net (a) | | 1,890 | | | 2,150 | |
| Total lease assets | | | | $ | 36,630 | | | $ | 33,950 | |
| Liabilities | | | | | | |
| Current: | | | | | | |
| Operating leases | | Lease liabilities, current portion | | $ | 7,360 | | | $ | 3,480 | |
| Finance leases | | Lease liabilities, current portion | | 700 | | | 620 | |
| Long-term: | | | | | | |
| Operating leases | | Lease liabilities | | 30,940 | | | 31,080 | |
| Finance leases | | Lease liabilities | | 210 | | | 730 | |
| Total lease liabilities | | | | $ | 39,210 | | | $ | 35,910 | |
| | | | | | |
__________________________
(a) Finance leases were recorded net of accumulated depreciation of $0.9 million and $0.7 million as of September 30, 2026 and December 31, 2025, respectively.
The components of lease expense are as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Three months ended September 30, | | Nine months ended September 30, |
| | Statement of Income Location | | 2026 | | 2025 | | 2026 | | 2025 |
| Operating lease cost | | Cost of sales and Selling, general and administrative expenses | | $ | 2,180 | | | $ | 2,230 | | | $ | 6,490 | | | $ | 6,270 | |
| Finance lease cost: | | | | | | | | | | |
| Depreciation of lease assets | | Cost of sales | | 60 | | | 60 | | | 180 | | | 190 | |
| Interest on lease liabilities | | Interest expense | | — | | | 10 | | | 20 | | | 30 | |
| Short-term, variable and other lease costs | | Cost of sales and Selling, general and administrative expenses | | 1,030 | | | 890 | | | 3,010 | | | 2,620 | |
| Total lease cost | | | | $ | 3,270 | | | $ | 3,190 | | | $ | 9,700 | | | $ | 9,110 | |
Maturities of lease liabilities are as follows (dollars in thousands):
| | | | | | | | | | | | | | |
| Year ended December 31, | | Operating Leases | | Finance Leases |
| 2026 (excluding the nine months ended September 30, 2026) | | $ | 2,750 | | | $ | 220 | |
| 2027 | | 8,980 | | | 740 | |
| 2028 | | 8,490 | | | — | |
| 2029 | | 7,330 | | | — | |
| 2030 | | 6,140 | | | — | |
| Thereafter | | 9,610 | | | — | |
| Total lease payments | | 43,300 | | | 960 | |
| Less: Imputed interest | | (5,000) | | | (50) | |
| Present value of lease liabilities | | $ | 38,300 | | | $ | 910 | |
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Other information related to the Company's leases are as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Cash paid for amounts included in the measurement of lease liabilities: | | | | | | | | |
| Operating cash flows from operating leases | | $ | 2,010 | | | $ | 1,940 | | | $ | 5,750 | | | $ | 5,670 | |
| Operating cash flows from finance leases | | — | | | 10 | | | 20 | | | 30 | |
| Financing cash flows from finance leases | | 130 | | | 130 | | | 400 | | | 370 | |
| Lease assets obtained in exchange for new lease liabilities: | | | | | | | | |
| Operating leases | | — | | | — | | | 8,570 | | | 4,250 | |
| | | | | | | | |
The weighted-average remaining lease term of the Company's operating leases and finance leases as of September 30, 2026 is 5.3 years and 0.9 years, respectively. The weighted-average discount rate for the operating leases and finance leases as of September 30, 2026 is 4.7% and 2.6%, respectively.
13. Other Long-term Liabilities
Other long-term liabilities consist of the following components (dollars in thousands):
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| Non-current asbestos-related liabilities | | $ | 30,620 | | | $ | 32,700 | |
| Other long-term liabilities | | 27,080 | | | 33,140 | |
| Total other long-term liabilities | | $ | 57,700 | | | $ | 65,840 | |
14. Commitments and Contingencies
Asbestos
As of September 30, 2026, the Company was a party to 717 pending cases involving an aggregate of 5,309 claimants primarily alleging personal injury from exposure to asbestos containing materials formerly used in gaskets (both encapsulated and otherwise) manufactured or distributed by its former Lamons division and certain other related subsidiaries for use primarily in the petrochemical, refining and exploration industries. The following chart summarizes the number of claims, number of claims filed, number of claims dismissed, number of claims settled, the average settlement amount per claim and the total defense costs, at the applicable date and for the applicable periods:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Claims pending at beginning of period | | Claims filed during period | | Claims dismissed during period | | Claims settled during period | | Claims pending at end of period | | Average settlement amount per claim during period | | Total defense costs during period |
| Nine Months Ended September 30, 2026 | | 5,080 | | | 352 | | | 89 | | | 34 | | | 5,309 | | | $ | 13,602 | | | $ | 1,822,000 | |
| Fiscal Year Ended December 31, 2025 | | 4,968 | | | 302 | | | 157 | | | 33 | | | 5,080 | | | $ | 18,091 | | | $ | 1,580,000 | |
In addition, the Company acquired various companies to distribute its products that had distributed gaskets of other manufacturers prior to acquisition. The Company believes that many of its pending cases relate to locations at which none of its gaskets were distributed or used.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The Company may be subjected to significant additional asbestos-related claims in the future, and will aggressively defend or reasonably resolve, as appropriate. The cost of settling cases in which product identification can be made may increase, and the Company may be subjected to further claims in respect of the former activities of its acquired gasket distributors. The cost of claims varies as claims may be initially made in some jurisdictions without specifying the amount sought or by simply stating the requisite or maximum permissible monetary relief, and may be amended to alter the amount sought. The large majority of claims do not specify the amount sought. Of the 5,309 claims pending at September 30, 2026, 35 set forth specific amounts of damages (other than those stating the statutory minimum or maximum). At September 30, 2026, of the 35 claims that set forth specific amounts, there were no claims seeking more than $5 million for punitive damages. Below is a breakdown of the compensatory damages sought for those claims seeking specific amounts:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Compensatory | | |
| Range of damages sought (dollars in millions) | | | | | | | | $0.0 to $0.6 | | $0.6 to $5.0 | | $5.0+ | | | | | | |
| Number of claims | | | | | | | | — | | 5 | | 30 | | | | | | |
Relatively few claims have reached the discovery stage and even fewer claims have gone past the discovery stage. Total settlement costs (exclusive of defense costs) for all such cases, some of which were filed over 30 years ago, have been $14.7 million. All relief sought in the asbestos cases is monetary in nature. Based on the settlements made to date and the number of claims dismissed or withdrawn for lack of product identification, the Company believes that the relief sought (when specified) does not bear a reasonable relationship to its potential liability.
The Company records a liability for asbestos-related claims, which includes both known and unknown claims, based on a study from the Company’s third-party actuary, the Company's review of the study, as well as the Company’s own review of asbestos claims and claim resolution activity.
In 2025, the Company commissioned its actuary to update the asbestos study based on data as of July 31, 2025, which yielded a range of possible future liability of $36.6 million to $48.9 million, before consideration of any potential insurance recoveries. The Company did not believe any amount within the range of potential outcomes represented a better estimate than another given the many factors and assumptions inherent in the projections, and therefore recorded a pre-tax charge of $8.0 million to increase the liability estimate to $36.6 million, at the low end of the range. As of September 30, 2026, and December 31, 2025, the Company’s total asbestos-related liability was $33.5 million and $35.5 million, respectively, and is included in accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheet. It is reasonably possible that a change in the estimate could occur in the near term.
The Company’s primary insurance, which covered approximately 40% of historical costs related to settlement and defense of asbestos litigation, expired in November 2018, upon which the Company became solely responsible for defense costs and indemnity payments. The Company is party to a coverage-in-place (CIP) agreement (entered into in 2006) with its first level excess carriers regarding the coverage to be provided to the Company for asbestos-related claims. The CIP agreement makes asbestos defense costs and indemnity insurance coverage available to the Company that might otherwise be disputed by the carriers and provides a methodology for the administration of such expenses. Prior to the commencement of coverage under this agreement, the Company was solely responsible for defense costs and indemnity payments. During 2025, the Company reached the threshold of qualified future settlements required to commence excess carrier insurance coverage under the CIP agreement and began transitioning the administration and settlement of asbestos defense costs and indemnity payments to the insurance carriers. During the three months ended December 31, 2025, the Company reassessed the facts and circumstances surrounding the CIP agreement with the consortium of insurance companies and deemed the realization of the claim for loss recovery probable and reasonably estimable and recognized an insurance recovery asset of $35.8 million, which was commensurate with the assumptions used to calculate the asbestos liability. As of September 30, 2026, and December 31, 2025, the Company's total insurance recovery asset was $32.7 million and $34.7 million. The Company will continue to reassess its estimate of insurance recoveries and corresponding accounting for any such recoveries as the facts and circumstances change.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Changes in the carrying amount of the asbestos liability and insurance recovery asset for the nine months ended September 30, 2026 and 2025 are summarized as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | |
| | Asbestos Liability | | Insurance Recovery Asset | | Net |
| Balance, December 31, 2025 | | $ | (35,530) | | | $ | 34,700 | | | $ | (830) | |
| | | | | | |
| Payments | | 2,080 | | | (2,020) | | | 60 | |
| Balance, September 30, 2026 | | $ | (33,450) | | | $ | 32,680 | | | $ | (770) | |
| Current portion | | $ | (2,830) | | | $ | 2,820 | | | |
| Non-current portion | | $ | (30,620) | | | $ | 29,860 | | | |
| | | | | | | | | | | | | | | | | | | | |
| | Asbestos Liability | | Insurance Recovery Asset | | Net |
| Balance, December 31, 2024 | | $ | (29,660) | | | $ | — | | | $ | (29,660) | |
| Asbestos remeasurement | | (8,030) | | | — | | | (8,030) | |
| Payments | | 1,090 | | | — | | | 1,090 | |
| Balance, September 30, 2025 | | $ | (36,600) | | | $ | — | | | $ | (36,600) | |
| Current portion | | $ | (2,830) | | | $ | — | | | |
| Non-current portion | | $ | (33,770) | | | $ | — | | | |
Based upon the Company's experience to date, including the trend in annual defense and settlement costs incurred to date, and other available information (including the availability of excess insurance), the Company does not believe these cases will have a material adverse effect on its financial position, results of operations, or cash flows.
Claims and Litigation
The Company is subject to other claims and litigation in the ordinary course of business, but does not believe that any such claim or litigation will have a material adverse effect on its financial position and results of operations or cash flows.
Environmental
The Company is responsible for environmental remediation at currently or previously owned facilities and waste sites, including sites defined under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly referred to as “Superfund” for which the Company has been named a potential responsible party. During the three and nine months ended September 30, 2026, and September 30, 2025, the Company recorded no charges related to environmental remediation costs. As of September 30, 2026, and December 31, 2025, the Company’s total environmental remediation obligation was $8.6 million and $9.4 million, respectively, which is primarily recorded within other long-term liabilities within the accompanying balance sheet. The accrual is primarily based on environmental cost estimates provided by third parties and represents the best estimate of the Company’s proportionate share of costs to be incurred for site remediation efforts. Actual costs incurred resulting from the ultimate resolution of these uncertainties could exceed the amount accrued.
15. Segment Information
The Company defines its segments consistent with how internally reported financial information is regularly reviewed by TriMas' President and Chief Executive Officer (chief operating decision maker) to analyze financial performance, make decisions, and allocate resources. TriMas reports its operations in two segments: Packaging and Specialty Products. Each of these segments has discrete financial information that is regularly evaluated by the chief operating decision maker. The chief operating decision maker uses segment operating profit when assessing segment performance, determining resource and capital allocation and developing overall strategic direction of the Company. The chief operating decision maker analyzes segment operating profit on a monthly basis by comparing actual results to forecasted and budgeted expectations to assess performance.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
See below for more information regarding the types of products and services provided within each reportable segment:
Packaging – TriMas' Packaging business develops and manufactures a broad array of dispensing products (such as foaming pumps, lotion, hand soap and sanitizer pumps, beverage dispensers, perfume sprayers, nasal sprayers and trigger sprayers), polymeric and steel caps and closures (such as food lids, flip-top closures, child resistant caps, beverage closures, fragrance and cosmetic caps, drum and pail closures, and flexible spouts), polymeric jar products, and consumable vascular delivery and diagnostic test components. These products serve a variety of consumer products submarkets including, but not limited to, beauty and personal care, food and beverage, home care, and life sciences (such as pharmaceutical, nutraceutical and medical), as well as industrial markets (including agricultural).
Specialty Products – TriMas' Specialty Products segment, which includes the Norris Cylinder business, designs, manufactures and distributes highly-engineered steel cylinders for use within industrial and aerospace markets. On January 31, 2025, the Company completed the divestiture of its Arrow Engine business within its Specialty Products segment. The Arrow Engine business manufactured and distributed natural gas-fired engines for remote power generation applications and compression systems for use within the North American industrial oil and gas markets.
Corporate consists of the corporate office and related corporate activities. Corporate expenses primarily include compensation, benefits, professional services, information technology and other administrative costs. Corporate assets consist primarily of cash and cash equivalents, unallocated deferred tax assets and prepaid assets. Corporate expenses and assets reconcile reportable segment information to the consolidated totals.
Segment activity is as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | |
| | Packaging | | | | Specialty Products | | Total |
| Three Months Ended September 30, 2026 | | | | | | | | |
| Net sales | | $ | 147,590 | | | | | $ | 31,150 | | | $ | 178,740 | |
| Cost of sales | | (113,070) | | | | | (32,040) | | | |
| Selling, general and administrative expenses | | (16,320) | | | | | (1,070) | | | |
Other segment items (a) | | — | | | | | (100) | | | |
| Segment operating profit (loss) | | $ | 18,200 | | | | | $ | (2,060) | | | $ | 16,140 | |
Corporate (b) | | | | | | | | (7,430) | |
| Interest expense | | | | | | | | (4,140) | |
Other income, net (c) | | | | | | | | 9,920 | |
| Income before income tax expense | | | | | | | | $ | 14,490 | |
| | | | | | | | |
| Three Months Ended September 30, 2025 | | | | | | | | |
| Net sales | | $ | 135,700 | | | | | $ | 30,320 | | | $ | 166,020 | |
| Cost of sales | | (104,980) | | | | | (26,570) | | | |
| Selling, general and administrative expenses | | (14,440) | | | | | (1,310) | | | |
Other segment items (a) | | 10 | | | | | (70) | | | |
| Segment operating profit | | $ | 16,290 | | | | | $ | 2,370 | | | $ | 18,660 | |
Corporate (d) | | | | | | | | (21,840) | |
| Interest expense | | | | | | | | (4,360) | |
| Other income, net | | | | | | | | 1,080 | |
| Income (loss) before income tax expense | | | | | | | | $ | (6,460) | |
| | | | | | | | |
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | |
| | Packaging | | | | Specialty Products | | Total |
| Nine Months Ended September 30, 2026 | | | | | | | | |
| Net sales | | $ | 429,680 | | | | | $ | 91,920 | | | $ | 521,600 | |
| Cost of sales | | (328,930) | | | | | (86,830) | | | |
| Selling, general and administrative expenses | | (49,290) | | | | | (3,520) | | | |
Other segment items (a) | | 10 | | | | | (80) | | | |
| Segment operating profit | | $ | 51,470 | | | | | $ | 1,490 | | | $ | 52,960 | |
Corporate (e) | | | | | | | | (26,500) | |
| Interest expense | | | | | | | | (13,500) | |
Other income, net (f) | | | | | | | | 22,140 | |
| Income before income tax expense | | | | | | | | $ | 35,100 | |
| | | | | | | | |
| Nine Months Ended September 30, 2025 | | | | | | | | |
| Net sales | | $ | 406,280 | | | | | $ | 83,950 | | | $ | 490,230 | |
| Cost of sales | | (308,550) | | | | | (76,430) | | | |
| Selling, general and administrative expenses | | (44,190) | | | | | (4,970) | | | |
Other segment items (a) | | (20) | | | | | (70) | | | |
| Segment operating profit | | $ | 53,520 | | | | | $ | 2,480 | | | $ | 56,000 | |
Corporate (g) | | | | | | | | (44,640) | |
| Interest expense | | | | | | | | (13,430) | |
| Other income, net | | | | | | | | 1,310 | |
| Income (loss) before income tax expense | | | | | | | | $ | (760) | |
__________________________(a) Other segment items for each reportable segment includes net gain (loss) on dispositions of assets.
(b) Includes $0.8 million of system implementation costs, $0.2 million of mergers, acquisition, diligence and transaction costs, and $(0.3) million of realignment, severance and consulting costs.
(c) Includes $11.0 million of interest income on the invested cash proceeds from the sale of Aerospace.
(d) Includes $8.0 million of asbestos-related costs, $1.9 million of system implementation costs, and $0.5 million of realignment.
(e) Includes $2.7 million of system implementation costs, $1.1 million of realignment and severance costs, and $1.1 million of mergers, acquisition, diligence and transaction costs.
(f) Includes $23.9 million of interest income on the invested cash proceeds from the sale of Aerospace.
(g) Includes $8.0 million of asbestos-related costs $7.5 million of realignment, severance and consulting costs, $5.4 million gain on the sale of Arrow Engine, $4.3 million of system implementation costs and $0.4 million of mergers, acquisition, diligence and transaction costs.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Capital expenditures | | | | | | | | |
| Packaging | | $ | 5,400 | | | $ | 6,460 | | | $ | 14,140 | | | $ | 22,550 | |
| | | | | | | | |
| Specialty Products | | 1,140 | | | 990 | | | 3,820 | | | 4,850 | |
| Corporate | | 570 | | | 1,470 | | | 1,290 | | | 4,090 | |
| Total | | $ | 7,110 | | | $ | 8,920 | | | $ | 19,250 | | | $ | 31,490 | |
| | | | | | | | |
| Depreciation and amortization | | | | | | | | |
| Packaging | | $ | 8,450 | | | $ | 9,060 | | | $ | 26,250 | | | $ | 26,100 | |
| | | | | | | | |
| Specialty Products | | 700 | | | 690 | | | 2,250 | | | 2,340 | |
| Corporate | | 120 | | | 100 | | | 340 | | | 270 | |
| Total | | $ | 9,270 | | | $ | 9,850 | | | $ | 28,840 | | | $ | 28,710 | |
| | | | | | | | | | | | | | |
| | September 30, 2026 | | December 31, 2025 |
| Total Assets | | | | |
| Packaging | | $ | 877,420 | | | $ | 855,080 | |
| | | | |
| Specialty Products | | 83,280 | | | 73,890 | |
Corporate(a) | | 1,186,210 | | | 112,660 | |
| Total | | $ | 2,146,910 | | | $ | 1,041,630 | |
(a) Corporate total assets as of September 30, 2026, includes $1,123.4 million of cash, primarily due to proceeds received on the sale of the Company's Aerospace segment and a $32.7 million asbestos-related insurance recovery asset. Corporate total assets as of December 31, 2025, includes a $53.9 million deferred tax asset as a result of the planned divestiture of Aerospace and a $34.7 million asbestos-related insurance recovery asset.
16. Equity Awards
Stock Options
Information related to stock options at September 30, 2026 is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Number of Stock Options | | Weighted Average Option Price | | Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value |
| Outstanding at January 1, 2026 | | 900,000 | | | $ | 41.11 | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Outstanding at September 30, 2026 | | 900,000 | | | $ | 41.11 | | | 8.7 | | $ | 1,580,000 | |
As of September 30, 2026, there was $3.2 million of unrecognized compensation cost related to stock options that is expected to be recorded over a weighted average period of 1.3 years.
The Company recognized approximately $0.4 million and $1.9 million of stock-based compensation expense related to stock options during the three and nine months ended September 30, 2026, respectively, and $0.7 million and $0.8 million of stock-based compensation expense related to stock options during the three and nine months ended September 30, 2025, respectively. The stock-based compensation expense is included in selling, general and administrative expenses in the accompanying consolidated statement of income.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Restricted Stock Units
The Company awarded the following restricted stock units ("RSUs") during the nine months ended September 30, 2026:
•Granted 88,382 RSUs to certain employees, which are subject only to a service condition and vest ratably over two or three years so long as the employee remains with the Company;
•Granted 22,824 RSUs to its non-employee independent directors, which fully vest one year from date of grant so long as the director and/or Company does not terminate the director's service prior to the vesting date;
•Issued 1,255 RSUs related to director fee deferrals as certain of the Company's directors elected to defer all or a portion of their director fees and to receive the amount in Company common stock at a future date; and
•Issued 15 RSUs to certain employees related to dividend equivalent rights on existing equity awards.
During 2026, the Company also awarded 39,379 performance-based RSUs to certain Company key employees which vest three years from the grant date as long as the employee remains with the Company. These awards are initially earned 50% based upon the Company's achievement of an earnings per share ("EPS") metric and 50% based upon the Company's return on invested capital ("ROIC") metric over a period beginning January 1, 2026 and ending December 31, 2028. The total EPS and ROIC performance-based RSUs initially earned shall be subject to modification based on the Company's total shareholder return ("TSR") relative to the TSR of the common stock of a pre-defined industry peer-group, measured over the performance period. TSR is calculated as the Company's average closing stock price for the 20 trading days at the end of the performance period plus Company dividends, divided by the Company's average closing stock price for the 20 trading days prior to the start of the performance period. The Company estimates the grant-date fair value subject to a market condition using a Monte Carlo simulation model, using the following weighted average assumptions: risk-free rate of 3.74% and annualized volatility of 29.5%. Depending on the performance achieved for these two metrics, the amount of shares earned, if any, can vary for each metric from 0% of the target award to a maximum of 220% of the target.
The following disclosures related to restricted stock units include both continuing and discontinued operations.
Information related to RSUs at September 30, 2026 is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Number of Unvested RSUs | | Weighted Average Grant Date Fair Value | | Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value |
| Outstanding at January 1, 2026 | | 1,009,137 | | | $ | 26.01 | | | | | |
| Granted | | 151,855 | | | 35.74 | | | | | |
| Vested | | (361,988) | | | 25.68 | | | | | |
| Cancelled | | (206,892) | | | 28.13 | | | | | |
| Outstanding at September 30, 2026 | | 592,112 | | | $ | 27.97 | | | 1.0 | | $ | 22,850,000 | |
As of September 30, 2026, there was $5.1 million of unrecognized compensation cost related to unvested RSUs that is expected to be recorded over a weighted average period of 2.0 years.
The Company recognized stock-based compensation expense related to RSUs from continuing operations of $1.1 million and $5.1 million for the three and nine months ended September 30, 2026, respectively, and $2.1 million and $6.2 million for the three and nine months ended September 30, 2025, respectively. The stock-based compensation expense from continuing operations is included in selling, general and administrative expenses in the accompanying consolidated statement of income.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
17. Earnings per Share
Net income (loss) is divided by the weighted average number of common shares outstanding during the period to calculate basic earnings (loss) per share. Diluted earnings (loss) per share is calculated to give effect to RSUs and stock options. The following table summarizes the dilutive effect of RSUs and stock options on common stock for the three and nine months ended September 30, 2026, and 2025:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Weighted average common shares—basic | | 35,759,542 | | | 40,650,933 | | | 36,354,394 | | | 40,634,527 | |
| Dilutive effect of restricted stock units | | 292,202 | | | — | | | 376,714 | | | — | |
| Dilutive effect of stock options | | 11,912 | | | — | | | 7,049 | | | — | |
| Weighted average common shares—diluted | | 36,063,656 | | | 40,650,933 | | | 36,738,157 | | | 40,634,527 | |
Anti-dilutive shares excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2026, were 606,237 and 768,746 shares, respectively. Anti-dilutive shares excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2025, were 1,362,389 and 696,619 shares, respectively.
In February 2026, the Company announced its Board of Directors had authorized the Company to increase the purchase of its common stock up to $150 million in the aggregate, adding to the $48.9 million remaining under the previous authorization. During the three and nine months ended September 30, 2026, the Company purchased 233,150 and 2,229,471 shares of its outstanding common stock for $9.3 million and $82.7 million, respectively. During the three months ended September 30, 2025, no shares were purchased. During the nine months ended September 30, 2025, the Company purchased 106,220 shares of its outstanding common stock for $2.3 million. As of September 30, 2026, the Company had $67.3 million remaining under the repurchase authorization.
Holders of common stock are entitled to dividends at the discretion of the Company's Board of Directors. During the three and nine months ended September 30, 2026, the Company's quarterly cash dividends declared were $0.04 per share of common stock and total dividends declared and paid on common shares were $1.5 million and $4.4 million, respectively. In the three and nine months ended September 30, 2025, the Company's quarterly cash dividends declared were $0.04 per share of common stock and total dividends declared and paid on common shares were $1.7 million and $5.0 million, respectively.
18. Defined Benefit Plans
Net periodic pension benefit costs for the Company's defined benefit pension plans cover certain foreign employees, union hourly employees and salaried employees. The components of net periodic benefit cost are as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Service costs | | $ | 70 | | | $ | 140 | | | $ | 260 | | | $ | 410 | |
| Interest costs | | 180 | | | 310 | | | 670 | | | 950 | |
| Expected return on plan assets | | (200) | | | (250) | | | (740) | | | (760) | |
| | | | | | | | |
| Settlement and curtailment losses | | — | | | — | | | 1,680 | | | — | |
| Amortization of net loss | | 60 | | | 30 | | | 190 | | | 80 | |
| Net periodic benefit cost | | $ | 110 | | | $ | 230 | | | $ | 2,060 | | | $ | 680 | |
The service cost component of net periodic benefit cost is recorded in cost of goods sold and selling, general and administrative expenses, while non-service cost components are recorded in other income (expense), net in the accompanying consolidated statement of income. The service cost related to discontinued operations included in the table above was $0.1 million for the nine months ended September 30, 2026, and $0.1 million and $0.2 million for the three and nine months ended September 30, 2025, respectively.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
During the nine months ended September 30, 2026, the Company recognized a non-cash, pre-tax settlement charge of $1.7 million which was recorded within the results of discontinued operations.
The Company contributed $0.7 million to its defined benefit pension plans during the nine months ended September 30, 2026. The Company expects to contribute $0.9 million to its defined benefit pension plans for the full year 2026.
19. Other Comprehensive Income (Loss)
Changes in AOCI by component for the nine months ended September 30, 2026 are summarized as follows, net of tax (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Defined Benefit Plans | | Derivative Instruments | | Foreign Currency Translation | | Total |
| Balance, December 31, 2025 | | $ | (8,550) | | | $ | 4,720 | | | $ | 3,820 | | | $ | (10) | |
Net unrealized gains (losses) arising during the period (a) | | 320 | | | 3,400 | | | (9,170) | | | (5,450) | |
Less: Net realized losses reclassified to net income (b) | | (1,330) | | | — | | | (1,160) | | | (2,490) | |
| Net current-period other comprehensive income (loss) | | 1,650 | | | 3,400 | | | (8,010) | | | (2,960) | |
| | | | | | | | |
| Balance, September 30, 2026 | | $ | (6,900) | | | $ | 8,120 | | | $ | (4,190) | | | $ | (2,970) | |
__________________________
(a) Defined benefit plans, net of income tax of $0.1 million. See Note 18, "Defined Benefit Plans," for additional details. Derivative instruments, net of income tax of $1.2 million. See Note 11, "Derivative Instruments," for further details.
(b) Defined benefit plans, net of income tax of $0.4 million. See Note 18, "Defined Benefit Plans," for additional details.
Changes in AOCI by component for the nine months ended September 30, 2025 are summarized as follows, net of tax (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Defined Benefit Plans | | Derivative Instruments | | Foreign Currency Translation | | Total |
| Balance, December 31, 2024 | | $ | (8,010) | | | $ | 16,300 | | | $ | (26,840) | | | $ | (18,550) | |
Net unrealized gains (losses) arising during the period (a) | | — | | | (12,070) | | | 32,100 | | | 20,030 | |
| Less: Net realized losses reclassified to net income | | (30) | | | — | | | — | | | (30) | |
| Net current-period other comprehensive income (loss) | | 30 | | | (12,070) | | | 32,100 | | | 20,060 | |
| | | | | | | | |
| Balance, September 30, 2025 | | $ | (7,980) | | | $ | 4,230 | | | $ | 5,260 | | | $ | 1,510 | |
__________________________
(a) Derivative instruments, net of income tax of $3.9 million. See Note 11, "Derivative Instruments," for further details.
20. Income Taxes
The effective income tax rate for the three months ended September 30, 2026 and 2025 was 20.8% and 24.3%, respectively. The Company recorded income tax expense of $3.0 million for the three months ended September 30, 2026, compared to income tax benefit of $1.6 million for the three months ended September 30, 2025. The decrease in the effective tax rate was primarily due to the recognition of approximately $0.9 million of tax benefit related to foreign tax loss carry forwards.
The effective income tax rate for the nine months ended September 30, 2026 and 2025 was 23.1% and 28.9%, respectively. The Company recorded income tax expense of $8.1 million for the nine months ended September 30, 2026 and an income tax benefit of $0.2 million for the nine months ended September 30, 2025. The change in the effective tax rate was primarily driven by changes in the jurisdictional mix of income and losses, which had a greater proportional impact on the effective income tax rate in the prior-year period, and the recognition of approximately $0.9 million of tax benefits related to foreign tax loss carryforwards in the current-year period.
Table of Contents
TRIMAS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Production Tax Credits
During the three months ended September 30, 2026, the Company purchased $82.6 million of 2025 transferable production tax credits (“PTCs”) at a 7% discount, representing an aggregate purchase price of approximately $76.8 million and an income tax benefit of approximately $5.8 million, of which $5.7 million was recorded within discontinued operations. The Company’s intraperiod income tax allocation methodology determines the allocation of the purchase discount benefit between continuing and discontinued operations. The allocation affects the presentation of income tax expense between continuing and discontinued operations but does not affect the Company’s consolidated net income or total income tax benefit.
21. Subsequent Events
On October 22, 2026, the Company announced that its Board of Directors had declared a cash dividend of $0.04 per share of TriMas Corporation common stock, which will be payable on November 12, 2026, to shareholders of record as of the close of business on November 5, 2026.
On October 22, 2026, the Company signed an agreement to sell its flexible bag-in-box product line within the Packaging segment. The sale closed on November 2, 2026.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The statements in the discussion and analysis regarding industry outlook, our expectations regarding the performance of our business and the other non-historical statements in the discussion and analysis are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under the heading "Forward-Looking Statements," at the beginning of this report. Our actual results may differ materially from those contained in or implied by any forward-looking statements. You should read the following discussion together with the Company's reports on file with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025.
Introduction
TriMas designs, develops and manufactures a diverse set of products primarily for the consumer products and industrial markets through its TriMas Packaging and Specialty Products groups. Our wide range of innovative products is designed and engineered to solve application-specific challenges that our customers face. We believe our businesses share important and distinguishing characteristics, including: innovative product technologies and features; a high degree of customer approved processes and qualifications; established distribution networks; modest capital investment requirements; strong cash flow conversion and long-term growth opportunities. While the majority of our revenue is in the United States, we manufacture and supply products globally to a wide range of companies. We report our business activity in two segments: Packaging and Specialty Products.
On March 16, 2026, we completed the previously announced sale of Aerospace to an affiliate of Tinicum L.P., and funds managed by Blackstone, Inc., pursuant to an Equity Purchase Agreement dated as of November 4, 2025 (the "Purchase Agreement"), for a purchase price of approximately $1,457.1 million, subject to certain adjustments as set forth in the Purchase Agreement, which were finalized during the third quarter of 2026. The historical results for Aerospace are reported in our consolidated statement of income and consolidated balance sheet as a discontinued operation for all periods presented in the financial statements.
Key Factors Affecting Our Reported Results
Demand for the products our businesses produce and results of operations depend upon general economic conditions. We serve customers in industries that are highly competitive, and that may be significantly impacted by changes in economic or geopolitical conditions.
Our results of operations have been materially impacted by macroeconomic conditions over the past few years, including cost inflation (raw materials, wage rates and freight) and a lack of material, and in certain regions, skilled labor availability. In 2025, the U.S. government implemented tariffs under the International Emergency Economic Powers Act ("IEEPA"), which created uncertainty regarding material costs, future tariffs, including any retaliatory tariffs imposed by other countries, or other potential governmental actions. These tariffs have increased the costs of certain products sourced from non-U.S. countries.
In February 2026, the U.S. Supreme Court ruled that the 2025 IEEPA tariffs were unlawful. Following this ruling, the U.S. government implemented certain other tariffs, which expired in late July 2026. To date, the changes in the tariffs, on an overall basis, have not had a significant impact on our results of operations. We will continue to monitor the situation and evaluate the impact of any replacement tariffs or policy changes on our business, including the potential for cost recovery and future tariff exposure.
Overall, our third quarter 2026 net sales increased $12.7 million, or 7.7%, compared to third quarter 2025. Net sales increased 2.7% in our Specialty Products segment as compared to the prior year quarter due to increased market demand for steel cylinders. Organic sales increased 8.2% within our Packaging segment, compared to third quarter 2025, due to improved customer demand in our end markets. Our overall sales increase included $0.8 million of currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of a weakening U.S. dollar relative to foreign currencies.
The most significant drivers affecting our financial results in third quarter 2026 compared with third quarter 2025, other than as directly impacted by sales changes, were a charge to cost of sales for a quantity difference determined as part of an inventory count, as well as temporary manufacturing inefficiencies, machine downtime and labor productivity challenges in our cylinder business within our Specialty Products segment, interest income earned on the invested cash proceeds from the sale of our Aerospace business, and the year-over-year impact of a charge to update our asbestos liability based on our recent actuarial valuation in third quarter 2025. We also purchased $82.6 million of 2025 transferable production tax credits (“PTCs”) at a 7% discount during third quarter 2026, representing an aggregate purchase price of approximately $76.8 million and an income tax benefit of approximately $5.8 million, of which $5.7 million was recognized in discontinued operations.
During first quarter 2026, we invested the cash proceeds from the sale of our Aerospace business in highly liquid instruments, including U.S. Treasury‑backed money market funds and cash deposits that earned interest at a rate of approximately 3.9% during third quarter. During the three months ended September 30, 2026, we earned interest income of $11.0 million.
See the Results of Operations section below for additional information.
Additional Key Risks that May Affect Our Reported Results
We have executed meaningful realignment actions over the past few years to address variable and structural costs where demand has fallen. We will continue to assess and take further actions if required. As a result of the current period of macroeconomic inflation and uncertainty, including uncertainty regarding the scope and duration of current and future tariffs and trade actions, and the potential impact of such factors to our future results of operations, as well as if there is an impact to TriMas' overall performance and market capitalization, we may record additional cash and non-cash charges related to further realignment actions, asset impairments, including impairments to our goodwill, intangible assets, fixed assets, inventory or customer receivable account balances.
We believe our capital structure is in a strong position. We have sufficient cash and available liquidity under our revolving credit facility to meet our debt service obligations, capital expenditure requirements and other short-term and long-term obligations for the foreseeable future.
Critical factors affecting our ability to succeed include: our ability to generate organic growth through product development, cross-selling and extending product-line offerings, and our ability to quickly and cost-effectively introduce and successfully launch new products; our ability to recognize the benefits of and effectively deploy the net proceeds from the sale of Aerospace, our ability to acquire and integrate companies or products that supplement existing product lines, add adjacent distribution channels and new customers, or expand our geographic coverage; our ability to manage our cost structure more efficiently via supply chain management, internal sourcing and/or purchasing of materials, selective outsourcing and/or purchasing of support functions, working capital management, and greater leverage of our administrative functions; and our ability to absorb, or recover via commercial actions, inflationary or other cost increases, including tariffs and duties.
Our overall business does not experience significant seasonal fluctuation, other than our fourth quarter, which has tended to be the lowest net sales quarter of the year due to holiday shutdowns at certain customers or other customers deferring capital spending to the following year. A growing amount of our sales is derived from international sources, which exposes us to certain risks, including currency risks.
We are sensitive to price movements and availability of our raw materials supply. Our largest raw material purchases are for polypropylene, polyethylene, steel, aluminum, and other oil and metal-based purchased components, the costs for each of which are subject to volatility. There has also been volatility in certain of our input costs as a direct and indirect result of foreign trade policy as well as from geopolitical conditions. We will continue to take actions to mitigate such increases, including implementing commercial pricing adjustments, holding extra inventories, resourcing to alternate suppliers and insourcing of previously sourced products. If suppliers or subcontractors fail to meet contractual requirements, we may be unable to secure acceptable alternatives on reasonable terms or in time to meet customer commitments, which could result in increased costs and penalties, the assertion of force majeure clauses in contracts with customers and disruptions to our operations. Although we believe we are generally able to mitigate the impact of higher commodity costs and supply disruptions over time, we may experience additional material costs and disruptions in supply in the future and may not be able to pass along higher costs to our customers in the form of price increases or otherwise mitigate the impacts to our operating results.
Although we have escalator/de-escalator clauses in commercial contracts with certain of our customers to address fluctuations in input costs, or can modify prices based on market conditions to recover higher costs, our price increases generally lag the underlying input cost increase, and we cannot be assured of full cost recovery in the open market. If input costs increase at rapid rates, our ability to recover cost increases on a timely basis is made more difficult by the lag nature of these contracts.
Oil-based commodity costs are a significant driver of raw materials and purchased components used within our Packaging segment. As such, an increase in crude oil prices often is a precursor to rising polymeric raw material costs, for which we may experience a contractual commercial recovery lag. During 2026, geopolitical instability in the Middle East has contributed to volatility in global energy and logistics markets. These conditions have led to increased oil-based commodity costs, including resin and other input costs, which began to affect us in second quarter 2026 and remained volatile through third quarter 2026.
Each year our businesses target continuous improvement initiatives in an effort to reduce, or otherwise offset, the impact of increased input and conversion costs through increased throughput and yield rates, with a goal of at least covering inflationary and market cost increases. In addition, we continuously review our operating cost structures to ensure alignment with current market demand.
We continue to evaluate alternatives to redeploy the cash generated by our businesses, one of which includes returning capital to our shareholders. In February 2026, our Board of Directors authorized us to increase the purchase of our common stock up to $150 million in the aggregate, adding to the $48.9 million remaining under the previous authorization. During third quarter 2026, 233,150 shares were purchased. As of September 30, 2026, we had $67.3 million remaining under the repurchase authorization.
In addition, in third quarter 2026, we declared dividends of $0.04 per share of common stock and paid dividends of $1.5 million. We will continue to evaluate opportunities to return capital to shareholders through the purchase of our common stock, as well as dividends, depending on market conditions and other factors.
Segment Information and Supplemental Analysis
The following table summarizes financial information for our reportable segments for the three months ended September 30, 2026 and 2025 (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, |
| 2026 | | As a Percentage of Net Sales | | 2025 | | As a Percentage of Net Sales |
| Net Sales | | | | | | | |
| Packaging | $ | 147,590 | | | 82.6 | % | | $ | 135,700 | | | 81.7 | % |
| | | | | | | |
| Specialty Products | 31,150 | | | 17.4 | % | | 30,320 | | | 18.3 | % |
| Total | $ | 178,740 | | | 100.0 | % | | $ | 166,020 | | | 100.0 | % |
| Gross Profit (Loss) | | | | | | | |
| Packaging | $ | 34,520 | | | 23.4 | % | | $ | 30,720 | | | 22.6 | % |
| | | | | | | |
| Specialty Products | (890) | | | (2.9) | % | | 3,750 | | | 12.4 | % |
| Total | $ | 33,630 | | | 18.8 | % | | $ | 34,470 | | | 20.8 | % |
| Selling, General and Administrative Expenses | | | | | | | |
| Packaging | $ | 16,320 | | | 11.1 | % | | $ | 14,440 | | | 10.6 | % |
| | | | | | | |
| Specialty Products | 1,070 | | | 3.4 | % | | 1,310 | | | 4.3 | % |
| Corporate | 7,430 | | | N/A | | 13,890 | | | N/A |
| Total | $ | 24,820 | | | 13.9 | % | | $ | 29,640 | | | 17.9 | % |
| Operating Profit (Loss) | | | | | | | |
| Packaging | $ | 18,200 | | | 12.3 | % | | $ | 16,290 | | | 12.0 | % |
| | | | | | | |
| Specialty Products | (2,060) | | | (6.6) | % | | 2,370 | | | 7.8 | % |
| Corporate | (7,430) | | | N/A | | (21,840) | | | N/A |
| Total | $ | 8,710 | | | 4.9 | % | | $ | (3,180) | | | (1.9) | % |
| Depreciation | | | | | | | |
| Packaging | $ | 7,190 | | | 4.9 | % | | $ | 7,350 | | | 5.4 | % |
| | | | | | | |
| Specialty Products | 700 | | | 2.2 | % | | 690 | | | 2.3 | % |
| Corporate | 120 | | | N/A | | 100 | | | N/A |
| Total | $ | 8,010 | | | 4.5 | % | | $ | 8,140 | | | 4.9 | % |
| Amortization | | | | | | | |
| Packaging | $ | 1,260 | | | 0.9 | % | | $ | 1,710 | | | 1.3 | % |
| | | | | | | |
| Specialty Products | — | | | — | % | | — | | | — | % |
| Corporate | — | | | N/A | | — | | | N/A |
| Total | $ | 1,260 | | | 0.7 | % | | $ | 1,710 | | | 1.0 | % |
The following table summarizes detail on the year-over-year sales growth percentages for our reportable segments for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Third Quarter 2026 vs. Third Quarter 2025 |
| | Organic | | | | Divestitures | | Foreign Exchange | | Total |
| Consolidated TriMas Corporation | | 7.2 | % | | | | — | % | | 0.5 | % | | 7.7 | % |
| Packaging | | 8.2 | % | | | | — | % | | 0.6 | % | | 8.8 | % |
| Specialty Products | | 2.7 | % | | | | — | % | | — | % | | 2.7 | % |
The following table summarizes financial information for our reportable segments for the nine months ended September 30, 2026 and 2025 (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Nine months ended September 30, |
| 2026 | | As a Percentage of Net Sales | | 2025 | | As a Percentage of Net Sales |
| Net Sales | | | | | | | |
| Packaging | $ | 429,680 | | | 82.4 | % | | $ | 406,280 | | | 82.9 | % |
| | | | | | | |
| Specialty Products | 91,920 | | | 17.6 | % | | 83,950 | | | 17.1 | % |
| Total | $ | 521,600 | | | 100.0 | % | | $ | 490,230 | | | 100.0 | % |
| Gross Profit | | | | | | | |
| Packaging | $ | 100,750 | | | 23.4 | % | | $ | 97,730 | | | 24.1 | % |
| | | | | | | |
| Specialty Products | 5,090 | | | 5.5 | % | | 7,520 | | | 9.0 | % |
| Total | $ | 105,840 | | | 20.3 | % | | $ | 105,250 | | | 21.5 | % |
| Selling, General and Administrative Expenses | | | | | | | |
| Packaging | $ | 49,290 | | | 11.5 | % | | $ | 44,190 | | | 10.9 | % |
| | | | | | | |
| Specialty Products | 3,520 | | | 3.8 | % | | 4,970 | | | 5.9 | % |
| Corporate | 26,500 | | | N/A | | 41,990 | | | N/A |
| Total | $ | 79,310 | | | 15.2 | % | | $ | 91,150 | | | 18.6 | % |
| Operating Profit (Loss) | | | | | | | |
| Packaging | $ | 51,470 | | | 12.0 | % | | $ | 53,520 | | | 13.2 | % |
| | | | | | | |
| Specialty Products | 1,490 | | | 1.6 | % | | 2,480 | | | 3.0 | % |
| Corporate | (26,500) | | | N/A | | (44,640) | | | N/A |
| Total | $ | 26,460 | | | 5.1 | % | | $ | 11,360 | | | 2.3 | % |
| Depreciation | | | | | | | |
| Packaging | $ | 22,370 | | | 5.2 | % | | $ | 21,120 | | | 5.2 | % |
| | | | | | | |
| Specialty Products | 2,250 | | | 2.4 | % | | 2,340 | | | 2.8 | % |
| Corporate | 340 | | | N/A | | 270 | | | N/A |
| Total | $ | 24,960 | | | 4.8 | % | | $ | 23,730 | | | 4.8 | % |
| Amortization | | | | | | | |
| Packaging | $ | 3,880 | | | 0.9 | % | | $ | 4,980 | | | 1.2 | % |
| | | | | | | |
| Specialty Products | — | | | — | % | | — | | | — | % |
| Corporate | — | | | N/A | | — | | | N/A |
| Total | $ | 3,880 | | | 0.7 | % | | $ | 4,980 | | | 1.0 | % |
The following table summarizes detail on the year-over-year sales growth percentages for our reportable segments for the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | September 30, 2026 YTD vs September 30, 2025 YTD |
| | Organic | | | | Divestitures | | Foreign Exchange | | Total |
| Consolidated TriMas Corporation | | 4.7 | % | | | | (0.3) | % | | 2.0 | % | | 6.4 | % |
| Packaging | | 3.4 | % | | | | — | % | | 2.4 | % | | 5.8 | % |
| | | | | | | | | | |
| Specialty Products | | 11.2 | % | | | | (1.7) | % | | — | % | | 9.5 | % |
Results of Operations
The principal factors impacting us during the three months ended September 30, 2026, compared with the three months ended September 30, 2025, were:
•Increase in demand for products in our major end markets;
•An inventory quantity adjustment as well as temporary manufacturing inefficiencies, machine downtime and labor productivity challenges within our Specialty Products segment;
•Interest income earned on the invested cash proceeds from the sale of our Aerospace business;
•The year-over-year impact of a charge to update our asbestos liability based on our recent actuarial valuation in third quarter 2025; and
•A $5.7 million tax benefit recognized in discontinued operations as a result of us purchasing transferable production tax credits during third quarter 2026.
Three Months Ended September 30, 2026 Compared with Three Months Ended September 30, 2025
Overall, net sales increased $12.7 million, or 7.7%, to $178.7 million for the three months ended September 30, 2026, as compared with $166.0 million in the three months ended September 30, 2025. Organic sales, excluding the impact of currency exchange, increased $11.9 million, or 7.2%, as organic sales increased 8.2% and 2.7% within our Packaging and Specialty Products segments, respectively, due to end market demand improvements and growth initiatives. In addition, net sales increased by $0.8 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening of the U.S. dollar relative to foreign currencies.
Gross profit margin (gross profit as a percentage of sales) approximated 18.8% for the three months ended September 30, 2026 and and 20.8% for the three months ended September 30, 2025, as the impact of increased sales levels, primarily in our Packaging segment, and the year-over-year impact of a $1.5 million write-off of certain inventory to the lower of cost or market in the third quarter of 2025 that did not repeat within our Packaging segment, were more than offset by lower gross profit in our Specialty Products segment resulting from a $2.1 million charge to cost of sales for a quantity difference determined as part of an inventory count as well as higher production costs and manufacturing inefficiencies.
Operating profit margin (operating profit as a percentage of sales) approximated 4.9% and (1.9)% for the three months ended September 30, 2026 and 2025, respectively. Operating profit increased $11.9 million to $8.7 million in the three months ended September 30, 2026, as compared to a loss of $3.2 million for the three months ended September 30, 2025, primarily due to an $8.0 million pre-tax charge related to updating our asbestos studies in the third quarter of 2025 that did not repeat, as well as a decrease in employee-related costs and overall general corporate expenses. Additionally, operating profit improved due to the year-over-year impact of a $1.5 million write-off of certain inventory to the lower of cost or market in the third quarter of 2025 that did not repeat within our Packaging segment. These increases were partially offset by a $2.1 million charge to cost of sales for a quantity difference determined as part of an inventory count, as well as higher production costs and manufacturing inefficiencies, all within our Specialty Products segment.
Interest expense decreased $0.2 million, to $4.1 million for the three months ended September 30, 2026, compared to $4.4 million for the three months ended September 30, 2025, due to a decrease in our weighted average borrowings on our revolving credit facility for the third quarter of 2026 as compared to the third quarter of 2025.
Other income increased $8.8 million to $9.9 million for the three months ended September 30, 2026, as compared to $1.1 million for the three months ended September 30, 2025, primarily due to $11.0 million of interest income on the invested cash proceeds from the sale of Aerospace, partially offset by increased losses on foreign currency transactions.
The effective income tax rate for the three months ended September 30, 2026 and 2025 was 20.8% and 24.3%, respectively. We recorded income tax expense of $3.0 million and an income tax benefit of $1.6 million for the three months ended September 30, 2026 and 2025, respectively. The change in the effective tax rate was primarily due to the recognition of approximately $0.9 million of tax benefit related to foreign tax loss carryforwards.
Income from continuing operations increased $16.4 million, to $11.5 million for the three months ended September 30, 2026, as compared to a loss of $4.9 million for the three months ended September 30, 2025. The increase was primarily the result of an increase in operating profit of $11.9 million, an increase of $8.8 million in other income, and a decrease in interest expense of $0.2 million, partially offset by an increase in income tax expense of $4.6 million.
See below for a discussion of operating results by segment.
Packaging. Net sales increased $11.9 million, or 8.8% (of which 8.2% was organic and 0.6% was foreign currency exchange), to $147.6 million in the three months ended September 30, 2026, as compared to $135.7 million in the three months ended September 30, 2025. Sales of products used in life sciences market increased $5.3 million, sales of dispensing products used primarily for beauty, personal care and home care applications increased by $4.2 million, sales of products used in food and beverage applications increased by $2.3 million, and sales of products used for industrial applications increased $0.8 million. These increases were partially offset by the decrease in sales of other consumer goods products of $1.6 million. Net sales increased by $0.8 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening of the U.S. dollar relative to foreign currencies, as compared to third quarter 2025.
Gross profit increased $3.8 million to $34.5 million, or 23.4% of sales, in the three months ended September 30, 2026, as compared to $30.7 million, or 22.6% of sales, in the three months ended September 30, 2025, primarily due to the impact of increased sales levels and the year-over-year impact of a $1.5 million write-off of certain inventory to the lower of cost or market in the third quarter of 2025 that did not repeat.
Selling, general and administrative expenses increased $1.9 million to $16.3 million, or 11.1% of sales, in the three months ended September 30, 2026, as compared to $14.4 million, or 10.6% of sales, in the three months ended September 30, 2025, primarily due to $1.1 million of higher realignment costs and higher overall general expenses, partially offset by lower employee-related costs and lower intangible asset amortization expense due to certain assets becoming fully amortized.
Operating profit increased $1.9 million to $18.2 million, or 12.3% of sales, in the three months ended September 30, 2026, as compared to $16.3 million, or 12.0% of sales, in the three months ended September 30, 2025, primarily due to higher sales levels, the write-off of certain inventory to the lower of cost or market in third quarter 2025 that did not repeat, and lower employee-related costs, partially offset by higher realignment costs.
Specialty Products. Net sales for the three months ended September 30, 2026 increased $0.8 million, or 2.7%, to $31.2 million, as compared to $30.3 million in the three months ended September 30, 2025, primarily due to higher demand and market share gains.
Gross profit (loss) decreased $4.6 million to a loss of $0.9 million, or 2.9% of sales, in the three months ended September 30, 2026, as compared to profit of $3.8 million, or 12.4% of sales, in the three months ended September 30, 2025. The most significant item during third quarter of 2026 was a $2.1 million charge to cost of sales for a quantity difference determined as part of an inventory count, which accumulated since the prior count in fourth quarter 2025. In addition, this segment continued to experience higher production costs due to inefficient ramping up of labor and machinery to meet the higher demand levels, significant levels of machine down-time, and higher overall material costs.
Selling, general and administrative expenses decreased $0.2 million to $1.1 million, or 3.4% of sales, in the three months ended September 30, 2026, as compared to $1.3 million, or 4.3% of sales, in the three months ended September 30, 2025, primarily due to lower employee-related costs.
Operating profit (loss) decreased $4.4 million to a loss of $2.1 million, or 6.6% of sales, in the three months ended September 30, 2026, as compared to profit of $2.4 million, or 7.8% of sales, in the three months ended September 30, 2025, as the impact of increased steel cylinder sales was more than offset by the impact of the inventory count adjustment as well as high production costs due to increased labor and production inefficiencies.
Corporate. Corporate expenses consist of the following (dollars in millions):
| | | | | | | | | | | | | | |
| | Three months ended September 30, |
| | 2026 | | 2025 |
| Corporate operating expenses | | $ | 5.7 | | | $ | 10.8 | |
| Non-cash stock compensation | | 1.5 | | | 2.8 | |
| Legacy expenses | | 0.2 | | | 8.3 | |
| | | | |
| Corporate expenses | | $ | 7.4 | | | $ | 21.8 | |
Corporate expenses decreased $14.4 million to $7.4 million for the three months ended September 30, 2026, from $21.8 million for the three months ended September 30, 2025, due to:
•Corporate operating expenses decreased $5.1 million to $5.7 million in the three months ended September 30, 2026 from $10.8 million in the three months ended September 30, 2025, primarily due to a $1.1 million decrease in costs associated with upgrades to certain of our information technology applications, as well as a decrease of $4.0 million of employee-related costs and overall general corporate expenses.
•We recognized an $8.0 million pre-tax charge related to updating our asbestos studies in the third quarter of 2025.
•Non-cash stock compensation decreased $1.3 million to $1.5 million in the three months ended September 30, 2026 from $2.8 million in the three months ended September 30, 2025, primarily due to employee separations in 2026.
Discontinued Operations. The results of discontinued operations consist of our Aerospace segment, for which we entered into a definitive agreement to sell on November 4, 2025. On March 16, 2026, we completed the sale for a purchase price of approximately $1,457.1 million, subject to certain adjustments as set forth in the Purchase Agreement, which adjustments we finalized during the third quarter of 2026. Income from discontinued operations was $5.9 million and $14.2 million for the three months ended September 30, 2026 and 2025, respectively. See Note 3, "Discontinued Operations," included in Part I, Item 1, "Notes to Consolidated Financial Statements," within this quarterly report on Form 10-Q for more information.
Nine Months Ended September 30, 2026 Compared with Nine Months Ended September 30, 2025
Overall, net sales increased $31.4 million, or 6.4%, to $521.6 million for the nine months ended September 30, 2026, as compared with $490.2 million in the nine months ended September 30, 2025. Organic sales, excluding the impact of currency exchange and divestitures, increased $23.1 million, or 4.7%, as organic sales increased 11.2% and 3.4% within our Specialty Products and Packaging segments, respectively, due to end market demand improvements and growth initiatives. These increases were partially offset by the impact of the divestiture of our Arrow Engine business in our Specialty Products segment. In addition, net sales increased by $9.7 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of a weakening U.S. dollar relative to foreign currencies.
Gross profit margin (gross profit as a percentage of sales) approximated 20.3% for the nine months ended September 30, 2026 and 21.5% for the nine months ended September 30, 2025. Gross profit margin decreased primarily due to the combination of a $2.1 million charge to cost of sales for a quantity difference determined as part of an inventory count recorded in third quarter 2026, which accumulated since the prior count in fourth quarter 2025, as well as significantly higher production costs and levels of machine down-time, and higher overall material costs, all primarily incurred during second and third quarters of 2026 within our Specialty Products segment. Additionally, gross profit margin decreased due to $1.9 million of higher realignment costs related to the closure and consolidation of our Atkins, Arkansas facility within our Packaging segment. These decreases were partially offset by the year-over-year impact of a $1.5 million write-off of certain inventory to the lower of cost or market in the third quarter of 2025 that did not repeat within our Packaging segment.
Operating profit margin (operating profit as a percentage of sales) approximated 5.1% and 2.3% for the nine months ended September 30, 2026 and 2025, respectively. Operating profit increased $15.1 million, to $26.5 million, for the nine months ended September 30, 2026, compared to $11.4 million for the nine months ended September 30, 2025, primarily due to an $8.0 million pre-tax charge related to updating our asbestos studies in the third quarter of 2025 that did not repeat, a decrease in consulting costs, as well as a decrease in employee-related costs and overall general corporate expenses. Additionally, operating profit improved due to the year-over-year impact of a $1.5 million write-off of certain inventory to the lower of cost or market in the third quarter of 2025 that did not repeat within our Packaging segment. These increases were partially offset by the year-over-year impact of a $5.4 million gain on the sale of Arrow Engine in the first nine months of 2025 that did not repeat, the combination of a $2.1 million charge to cost of sales for a quantity difference determined as part of an inventory count recorded in third quarter 2026, which accumulated since the prior count in fourth quarter 2025, as well as significantly higher production costs and levels of machine down-time within our Specialty Products segment, and $1.2 million of higher realignment costs primarily related to the closure and consolidation of our Atkins, Arkansas facility within our Packaging segment.
Interest expense increased $0.1 million, to $13.5 million, for the nine months ended September 30, 2026, as compared to $13.4 million for the nine months ended September 30, 2025, due to borrowing under our revolving credit facility at a higher rate in the first nine months of 2026 as compared to the first nine months of 2025.
Other income increased $20.8 million to $22.1 million, for the nine months ended September 30, 2026, from $1.3 million for the nine months ended September 30, 2025, as the $23.9 million of interest income earned on invested cash proceeds from the sale of our Aerospace business was partially offset by increased losses on foreign currency transactions.
The effective income tax rate for the nine months ended September 30, 2026 and 2025 was 23.1% and 28.9%, respectively. We recorded income tax expense of $8.1 million for the nine months ended September 30, 2026, as compared to an income tax benefit of $0.2 million for the nine months ended September 30, 2025. The change in the effective tax rate was primarily driven by changes in the jurisdictional mix of income and losses, which had a greater proportional impact on the effective income tax rate in the prior-year period, and the recognition of approximately $0.9 million of tax benefits related to foreign tax loss carryforwards in the current-year period.
Income from continuing operations increased by $27.5 million, to $27.0 million for the nine months ended September 30, 2026, compared to a loss of $0.5 million for the nine months ended September 30, 2025. The increase was primarily the result of an increase in other income of $20.8 million and an increase in operating profit of $15.1 million, partially offset by an increase in income tax expense of $8.3 million and an increase in interest expense of $0.1 million.
See below for a discussion of operating results by segment.
Packaging. Net sales increased $23.4 million, or 5.8% (of which 3.4% was organic and 2.4% was foreign currency exchange), to $429.7 million in the nine months ended September 30, 2026, as compared to $406.3 million in the nine months ended September 30, 2025. Sales of products used in life sciences market increased $13.5 million, sales of dispensing products used primarily for beauty, personal care and home care applications increased $4.4 million, and sales of products used for industrial applications increased $0.8 million. These increases were partially offset by the decrease in sales of other consumer goods products of $5.1 million. Net sales increased by $9.7 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening U.S. dollar relative to foreign currencies, as compared to 2025.
Gross profit increased $3.0 million to $100.8 million, or 23.4% of sales, in the nine months ended September 30, 2026, as compared to $97.7 million, or 24.1% of sales, in the nine months ended September 30, 2025, primarily due to the impact of increased sales levels and the year-over-year impact of a $1.5 million write-off of certain inventory to the lower of cost or market in the first nine months of 2025 that did not repeat. These increases were partially offset by $1.9 million of higher realignment costs related to the closure and consolidation of our Atkins, Arkansas facility.
Selling, general and administrative expenses increased $5.1 million to $49.3 million, or 11.5% of sales, in the nine months ended September 30, 2026, as compared to $44.2 million, or 10.9% of sales, in the nine months ended September 30, 2025, primarily due to $3.2 million of higher realignment costs related to the comprehensive reorganization of our Packaging segment and higher overall general expenses, partially offset by lower employee-related costs and lower intangible asset amortization expense due to certain assets becoming fully amortized.
Operating profit decreased $2.1 million to $51.5 million, or 12.0% of sales, in the nine months ended September 30, 2026, as compared to $53.5 million, or 13.2% of sales, in the nine months ended September 30, 2025, primarily due to higher realignment costs, partially offset by the impact of increased sales and the write-off of certain inventory to the lower of cost or market in third quarter 2025 that did not repeat.
Specialty Products. Net sales for the nine months ended September 30, 2026 increased $8.0 million, or 9.5% (of which 11.2% was organic and (1.7)% was due to the divestiture of Arrow Engine), to $91.9 million, as compared to $84.0 million in the nine months ended September 30, 2025. Sales of steel cylinders increased $9.4 million, or 11.4%, to $91.9 million, as compared to $82.5 million, primarily due to improved demand for industrial applications and market share gains. Arrow Engine contributed $1.4 million of sales in the nine months ended September 30, 2025. See Note 6, "Acquisitions and Sale of Business," included in Part I, Item 1, "Notes to Consolidated Financial Statements," within this quarterly report on Form 10-Q for more information.
Gross profit decreased $2.4 million to $5.1 million, or 5.5% of sales, in the nine months ended September 30, 2026, as compared to $7.5 million, or 9.0% of sales, in the nine months ended September 30, 2025. While gross profit increased based on the higher steel cylinder sales, this impact was more than offset by the combination of a $2.1 million charge to cost of sales for a quantity difference determined as part of an inventory count recorded in third quarter 2026, which accumulated since the prior count in fourth quarter 2025, as well as significantly higher production costs and levels of machine down-time, and higher overall material costs, all primarily incurred during second and third quarters of 2026. In addition, gross profit was impacted by the divestiture of our Arrow Engine business in January 2026.
Selling, general and administrative expenses decreased $1.5 million to $3.5 million, or 3.8% of sales, in the nine months ended September 30, 2026, as compared to $5.0 million, or 5.9% of sales, in the nine months ended September 30, 2025, primarily due to $1.2 million of incurred expenses related to our Arrow Engine business, which we divested in January 2025, and lower employee-related costs.
Operating profit decreased $1.0 million to $1.5 million, or 1.6% of sales, in the nine months ended September 30, 2026, as compared to $2.5 million, or 3.0% of sales, in the nine months ended September 30, 2025, primarily due to higher sales of our steel cylinders and lower selling, general and administrative expenses, partially offset by the impact of the inventory count adjustment as well as higher production costs, manufacturing inefficiencies, and the year-over-year impact from the divestiture of our Arrow Engine business.
Corporate. Corporate expenses, net consist of the following (dollars in millions):
| | | | | | | | | | | | | | |
| | Nine months ended September 30, |
| | 2026 | | 2025 |
| Corporate operating expenses | | $ | 19.1 | | | $ | 34.5 | |
| Non-cash stock compensation | | 7.0 | | | 7.0 | |
| Legacy expenses | | 0.4 | | | 8.5 | |
| Gain on disposition of assets | | — | | | (5.4) | |
| Corporate expenses | | $ | 26.5 | | | $ | 44.6 | |
Corporate expenses decreased $18.1 million to $26.5 million for the nine months ended September 30, 2026, from $44.6 million in the nine months ended September 30, 2025, due to:
•Corporate operating expenses decreased $15.4 million to $19.1 million in the nine months ended September 30, 2026 from $34.5 million in the nine months ended September 30, 2025, due to a $4.8 million decrease related to consulting costs and costs associated with actions to reorganize the corporate office in the first half of 2025 (exclusive of non-cash stock compensation), a $1.6 million decrease in costs associated with upgrades to certain of our information technology applications, as well as a decrease of $8.9 million in employee-related costs and overall general corporate expenses.
•We recognized an $8.0 million pre-tax charge related to updating our asbestos studies in the third quarter of 2025.
•Non-cash stock compensation remained flat at $7.0 million in both the nine months ended September 30, 2026, and 2025.
•We recognized a $5.4 million pre-tax gain in the nine months ended September 30, 2025, on the sale of our former Arrow Engine business.
Discontinued Operations. The results of discontinued operations consist of our Aerospace segment, for which we entered into a definitive agreement to sell on November 4, 2025. On March 16, 2026, we completed the sale for a purchase price of approximately $1,457.1 million, subject to certain adjustments as set forth in the Purchase Agreement, which adjustments were finalized during the third quarter of 2026. Income from discontinued operations, net of income tax expense, was $804.6 million for the nine months ended September 30, 2026, as compared to $39.0 million for the nine months ended September 30, 2025. See Note 3, "Discontinued Operations," included in Part I, Item 1, "Notes to Consolidated Financial Statements," within this quarterly report on Form 10-Q for more information.
Liquidity and Capital Resources
Cash Flows
Cash flows used for operating activities were $124.6 million for the nine months ended September 30, 2026, as compared to cash provided by operating activities of $75.9 million for the nine months ended September 30, 2025. Significant changes in cash flows provided by operating activities and the reasons for such changes were as follows:
•For the nine months ended September 30, 2026, we reported a use of $161.2 million in cash flows, based on reported net income of $831.6 million, which includes $27.0 million income from continuing operations and $804.6 million income from discontinued operations, and after considering the effects of non-cash items related to depreciation, amortization, and gain on dispositions of assets, amortization of debt issuance costs, changes in deferred income taxes, stock-based compensation, provision for losses on accounts receivable, and other operating activities. For the nine months ended September 30, 2025, we generated $91.0 million in cash flows based on reported net income of $38.4 million, which includes $0.5 million loss from continuing operations and $39.0 million income from discontinued operations, and after considering the effects of similar non-cash items.
•Increases in accounts receivable resulted in a use of cash of $46.3 million and $18.3 million for the nine months ended September 30, 2026 and 2025, respectively. The increased use of cash for each of the nine month periods is due primarily to the timing of sales and collection of cash related thereto within the periods. Days sales outstanding of receivables increased twelve days through the nine months ended September 30, 2026 primarily due to increased sales with customers that generally have longer payment terms, and decreased one day through the nine months ended September 30, 2025.
•We increased our investment in inventory by $15.4 million and $8.4 million for the nine months ended September 30, 2026 and nine months ended September 30, 2025, respectively. Our days sales in inventory decreased nine days through the nine months ended September 30, 2026, and was flat through the nine months ended September 30, 2025, as we continued to manage inventory levels, considering our supply needs, and balanced with sales growth across our segments.
•A decrease in prepaid expenses and other assets resulted in a source of cash of $12.5 million for the nine months ended September 30, 2026 and $8.3 million for the nine months ended September 30, 2025. These changes were primarily a result of the timing of payments made for income taxes and certain operating expenses.
•An increase in accounts payable and accrued liabilities resulted in a source of cash of $85.8 million and $3.3 million for the nine months ended September 30, 2026 and September 30, 2025, respectively. The increase in accounts payable and accrued liabilities for the nine months ended September 30, 2026, includes a liability for estimated tax payments of $67.6 million primarily related to the gain on the sale of Aerospace. Days accounts payable on hand (excluding the impact of income taxes payable for the nine months ended September 30, 2026) decreased by 16 days through the nine months ended September 30, 2026 and decreased four days through the nine months ended September 30, 2025. Our days accounts payable on hand fluctuate primarily as a result of the timing of payments made to suppliers and the mix of vendors and related terms.
Net cash provided by investing activities for the nine months ended September 30, 2026 was $1,417.5 million, while net cash used for investing activities was $59.6 million during the nine months ended September 30, 2025. During the nine months ended September 30, 2026, we invested $20.2 million in capital expenditures, as we continued our investment in growth, capacity and productivity-related capital projects. We also received combined net proceeds of $1,437.7 million from the sale of our Aerospace business and disposition of property and equipment. During the nine months ended September 30, 2025, we invested $43.7 million in capital expenditures, paid $37.7 million, net of cash acquired, to acquire GMT Aerospace, and received net proceeds of $21.8 million from the sale of our Arrow Engine business and disposition of property and equipment.
Net cash used for financing activities was $164.4 million for the nine months ended September 30, 2026, while net cash used for financing activities was $5.8 million during the nine months ended September 30, 2025. During the nine months ended September 30, 2026, we made net repayments of $72.7 million on our revolving credit facilities, purchased $82.7 million of our outstanding common stock, used a net cash amount of $4.5 million related to our stock compensation arrangements, and paid dividends of $4.4 million. Our reported net repayments from borrowings on our revolving credit facilities considers the impact of foreign currency translation. During the nine months ended September 30, 2025, we received net proceeds of $4.5 million from borrowings on our revolving credit facilities, paid $1.3 million for debt financing fees, purchased $2.3 million of outstanding common stock, used a net cash amount of $1.9 million related to our stock compensation arrangements, and paid dividends of $5.0 million.
Our Debt and Other Commitments
In March 2021, we issued $400.0 million aggregate principal amount of 4.125% senior notes due April 15, 2029 ("Senior Notes") at par value in a private placement under Rule 144A of the Securities Act of 1933, as amended ("Securities Act"). The Senior Notes accrue interest at a rate of 4.125% per annum, payable semi-annually in arrears on April 15 and October 15. The payment of principal and interest is jointly and severally guaranteed, on a senior unsecured basis, by certain subsidiaries of the Company. The Senior Notes are pari passu in right of payment with all existing and future senior indebtedness and effectively subordinated to all existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness.
We may redeem all or part of the Senior Notes at par (100% of principal amount), plus accrued and unpaid interest, if any, to the redemption date.
For the nine months ended September 30, 2026, our consolidated subsidiaries that do not guarantee the Senior Notes represented 38% of the total of guarantor and non-guarantor net sales, treating each as a consolidated group and excluding intercompany transactions between guarantor and non-guarantor subsidiaries. In addition, our non-guarantor subsidiaries represented 17% and 12% of the total guarantor and non-guarantor assets and liabilities, respectively, as of September 30, 2026, treating the guarantor and non-guarantor subsidiaries each as a consolidated group.
In March 2025, we amended our existing credit agreement ("Credit Agreement") to extend the maturity date. We incurred fees and expenses of $1.3 million related to the amendment, all of which was capitalized as debt issuance costs. We also recorded $0.1 million of non-cash expense related to the write-off of previously capitalized deferred financing fees. The Credit Agreement consists of a $250.0 million senior secured revolving credit facility, which permits borrowings denominated in specific foreign currencies, subject to a $125.0 million sub limit, maturing on March 31, 2030.
The Credit Agreement is subject to benchmark interest rates determined based on the currency denomination of borrowings, with British pound sterling borrowings subject to the Sterling Overnight Index Average, Euro borrowings to the Euro InterBank Offered Rate and U.S. dollar borrowings subject to the Secured Overnight Financing Rate, each plus a spread that ranges from 1.375% to 2.00% based upon the leverage ratio, as defined, as of the most recent determination date. Our revolving credit facility allows for the issuance of letters of credit, not to exceed $40.0 million in aggregate.
The Credit Agreement permits borrowings denominated in specific foreign currencies, subject to a $125.0 million sub limit. The Credit Agreement also provides for incremental revolving credit commitments in an amount not to exceed the greater of $200.0 million and an amount such that, after giving effect to such incremental commitments and the incurrence of any other indebtedness substantially simultaneously with the making of such commitments, the senior secured net leverage ratio, as defined in the Credit Agreement, is no greater than 3.00 to 1.00. The terms and conditions of any incremental revolving credit facility commitments must be no more favorable than the existing credit facility.
Amounts drawn under our revolving credit facility fluctuate daily based upon our working capital and other ordinary course needs. Availability under our revolving credit facility depends upon, among other things, compliance with our Credit Agreement's financial covenants. Our Credit Agreement contains various negative and affirmative covenants and other requirements affecting us and our subsidiaries, including the ability to, subject to certain exceptions and limitations, incur debt, liens, mergers, investments, loans, advances, guarantee obligations, acquisitions, asset dispositions, sale-leaseback transactions, hedging agreements, dividends and other restricted payments, transactions with affiliates, restrictive agreements and amendments to charters, bylaws, and other material documents. The terms of our Credit Agreement require us and our subsidiaries to meet certain restrictive financial covenants and ratios computed quarterly, including a maximum total net leverage ratio (total consolidated indebtedness plus outstanding amounts under any accounts receivable securitization facility, less the aggregate amount of certain unrestricted cash and unrestricted permitted investments, as defined, over consolidated EBITDA, as defined) and a minimum interest expense coverage ratio (consolidated EBITDA, as defined, over the sum of consolidated cash interest expense, as defined, and preferred dividends, as defined). Our permitted total net leverage ratio under the Credit Agreement is 4.00 to 1.00 as of September 30, 2026. If we were to complete an acquisition which qualifies for a Covenant Holiday Period, as defined in our Credit Agreement, then our permitted total net leverage ratio cannot exceed 4.50 to 1.00 during that period. Our actual total net leverage ratio was 1.77 to 1.00 at September 30, 2026. Our permitted interest expense coverage ratio under the Credit Agreement is 3.00 to 1.00 as of September 30, 2026. Our actual interest expense coverage ratio was N/A to 1.00 at September 30, 2026. In December 2025 and March 2026, we amended the Credit Agreement to update certain definitions used in ratio and indebtedness calculations due to the sale of the Aerospace segment. At September 30, 2026, we were in compliance with our financial covenants.
The following is a reconciliation of net income, as reported, which is a GAAP measure of our operating results, to Consolidated Bank EBITDA, as defined in our Credit Agreement, for the twelve months ended September 30, 2026 (dollars in thousands). We present Consolidated Bank EBITDA to show our performance under our financial covenants.
| | | | | | | | | | | | | | |
| | | | | | | | |
| | | | | | | | Twelve Months Ended September 30, 2026 |
| Net income | | | | | | | | $ | 913,270 | |
| Bank stipulated adjustments: | | | | | | | | |
| Interest expense | | | | | | | | 18,100 | |
| Income tax expense | | | | | | | | 208,470 | |
| Depreciation and amortization | | | | | | | | 48,050 | |
| Impairment charges and asset write-offs | | | | | | | | — | |
Non-cash compensation expense(1) | | | | | | | | 10,200 | |
| | | | | | | | |
| Other non-cash expenses or losses | | | | | | | | 220 | |
Non-recurring expenses or costs(2) | | | | | | | | 14,760 | |
| Extraordinary, non-recurring or unusual gains or losses | | | | | | | | (1,060,690) | |
| Effects of purchase accounting adjustments | | | | | | | | 350 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Permitted dispositions | | | | | | | | 780 | |
| Currency gains and losses | | | | | | | | 2,060 | |
| Interest income | | | | | | | | (24,090) | |
| Permitted dispositions EBITDA | | | | | | | | (40,500) | |
| Consolidated Bank EBITDA, as defined | | | | | | | | $ | 90,980 | |
| | | | | | | | |
| September 30, 2026 | |
| | |
| | |
Total Indebtedness, as defined(3) | $ | 160,900 | | |
| Consolidated Bank EBITDA, as defined | 90,980 | | |
| Total net leverage ratio | 1.77 | | x |
| Covenant requirement | 4.00 | | x |
| | | | | | | | | | | | | | |
| | | | | | | | |
| | | | | | | | Twelve Months Ended September 30, 2026 |
| Interest expense | | | | | | | | $ | 18,100 | |
| Bank stipulated adjustments: | | | | | | | | |
| Interest income | | | | | | | | (24,090) | |
| Non-cash amounts attributable to amortization of financing costs | | | | | | | | (970) | |
| | | | | | | | |
| Total Consolidated Cash Interest Expense, as defined | | | | | | | | $ | (6,960) | |
| | | | | | | | |
| September 30, 2026 | |
| Consolidated Bank EBITDA, as defined | $ | 90,980 | | |
| Total Consolidated Cash Interest Expense, as defined | (6,960) | | |
| Actual interest expense coverage ratio | N/A | x |
| Covenant requirement | 3.00 | | x |
_____________________________
(1) Non-cash compensation expenses resulting from the grant of equity awards.
(2) Non-recurring costs and expenses relating to diligence and transaction costs, system implementation costs, and business restructuring and severance costs.
(3) Includes $0.9 million of finance leases. The Credit Agreement allows up to $240.0 million in cash netting.
At September 30, 2026, we had no amounts outstanding under our revolving credit facility and had $243.8 million available after giving effect to $6.2 million of letters of credit issued and outstanding. At December 31, 2025, we had $72.8 million outstanding under our revolving credit facility and had $171.2 million available after giving effect to $6.0 million of letters of credit issued and outstanding. Our letters of credit are used for a variety of purposes, including support of certain operating lease agreements, vendor payment terms and other subsidiary operating activities, and to meet various states' requirements to self-insure workers' compensation claims, including incurred but not reported claims. After consideration of leverage restrictions contained in the Credit Agreement, as of September 30, 2026 we had $203.0 million of borrowing capacity available for general corporate purposes. Our borrowing capacity was not reduced by leverage restrictions contained in the Credit Agreement as of December 31, 2025.
We rely upon our cash flow from operations and available liquidity under our revolving credit facility to fund our debt service obligations and other contractual commitments, working capital and capital expenditure requirements. At the end of each quarter, we have historically used cash on hand from our domestic and foreign subsidiaries to pay down amounts outstanding under our revolving credit facility, as applicable.
Our weighted average borrowings during the nine months ended September 30, 2026 approximated $425.9 million, compared to $433.7 million during the nine months ended September 30, 2025. Our weighted average borrowings decreased year-over-year primarily due to borrowings made on our revolving credit facility in 2025 to fund certain investments in our former Aerospace segment. We fully repaid our revolving credit facility in first quarter 2026.
In May 2021, we, through one of our non-U.S. subsidiaries, entered into a revolving loan facility with a borrowing capacity of $4.0 million. The facility is guaranteed by TriMas Corporation. At September 30, 2026, we had no amounts outstanding on this loan facility.
Cash management related to our revolving credit facility is centralized. We monitor our cash position and available liquidity on a daily basis and forecast our cash needs on a weekly basis within the current quarter and on a monthly basis outside the current quarter over the remainder of the year. Our business and related cash forecasts are updated monthly.
The majority of our cash on hand as of September 30, 2026 is located within the U.S. Our available funding under our revolving credit facility is $203.0 million at September 30, 2026. Based on forecasted cash sources and requirements inherent in our business plans, we believe that our liquidity and capital resources, including anticipated cash flows from operations, will be sufficient to meet our debt service, capital expenditure and other short-term and long-term obligations for the foreseeable future, as well as dividends and share repurchases.
As of September 30, 2026, the majority of our cash was invested in liquid instruments, including U.S. Treasury Bills, U.S. Treasury‑backed money market funds and cash deposits with high‑credit‑quality financial institutions designated as Globally Systemically Important Banks. These investments earn interest at an average rate of 3.9%, and qualify as permitted investments under our Credit Agreement. We intend to maintain these investments until they are deployed for general corporate purposes, which may include, among other things, organic growth initiatives, strategically aligned acquisition opportunities, share repurchases, dividends, the repayment of outstanding indebtedness, including our Senior Notes, or a combination thereof. During the nine months ended September 30, 2026, we earned interest income of $23.9 million.
We are subject to variable interest rates on our revolving credit facility, which is subject to a benchmark interest rate determined based on the currency denomination of borrowings. At September 30, 2026, we had no amounts outstanding on our revolving credit facility and, therefore, no variable rate-based borrowings outstanding.
In addition to our long-term debt, we have other cash commitments related to leases. The majority of our lease transactions are accounted for as operating leases, and annual rent expense related thereto approximated $12.2 million in 2025. We expect leasing will continue to be an available financing option to fund future capital expenditure requirements.
In February 2026, we announced our Board of Directors had authorized us to increase the purchase of our common stock up to $150 million in the aggregate, adding to the $48.9 million remaining under the previous authorization. In the nine months ended September 30, 2026, we purchased 2,229,471 shares of our outstanding common stock for an aggregate purchase price of $82.7 million. Since the initial authorization through September 30, 2026, we have purchased 11,920,901 shares of our outstanding common stock for an aggregate purchase price of $368.4 million. We will continue to evaluate opportunities to return capital to shareholders through the purchase of our common stock and the payment of dividends, depending on market conditions, and other factors.
Market Risk
We conduct business in various locations throughout the world and are subject to market risk due to changes in the value of foreign currencies. The functional currencies of our foreign subsidiaries are primarily the local currency in the country of domicile. We manage these operating activities at the local level and revenues and costs are generally denominated in local currencies; however, results of operations and assets and liabilities reported in U.S. dollars will fluctuate with changes in exchange rates between such local currencies and the U.S. dollar.
We use derivative financial instruments to manage currency risks associated with our procurement activities denominated in currencies other than the functional currency of our subsidiaries and the impact of currency rate volatility on our earnings. As of September 30, 2026, we were party to foreign exchange forward and swap contracts to hedge changes in foreign currency exchange rates with notional amounts of $120.6 million. We also use cross-currency swap agreements to mitigate currency risks associated with the net investment in certain of our foreign subsidiaries. See Note 11, "Derivative Instruments," included in Part I, Item 1, "Notes to Consolidated Financial Statements," within this quarterly report on Form 10-Q for additional information.
We are also subject to interest risk as it relates to our long-term debt. We have historically used interest rate swap agreements to fix the variable portion of our debt to manage this risk, when applicable.
Common Stock
TriMas is listed in the NASDAQ Global Select Market. Our stock trades under the symbol "TRS."
Credit Rating
We and certain of our outstanding debt obligations are rated by Standard & Poor's and Moody's. Our ratings have been updated following our March 2026 sale of our Aerospace business. On October 29, 2026, Moody's lowered our Corporate Family Rating to B1, and changed our outlook from "under review for possible downgrade" to stable. Moody's also lowered their rating of our Senior Notes to B2. See Note 10, "Long-term Debt" included in Part I, Item 1, "Notes to Consolidated Financial Statements" within this quarterly report on Form 10-Q. On March 26, 2026, Standard & Poor's lowered their rating of our Senior Notes to B. Standard & Poor's also lowered the corporate credit rating to B+ and maintained its outlook as stable. If our credit ratings were to decline, our ability to access certain financial markets may become limited, our cost of borrowings may increase, the perception of us in the view of our customers, suppliers and security holders may worsen and as a result, we may be adversely affected.
Outlook
We entered 2026 with a clear strategic focus on strengthening our core businesses, building a more focused company following the Aerospace divestiture. We have advanced our organizational transformation by strengthening our leadership team, enhancing organizational accountability, streamlining our cost structure, advancing operational excellence initiatives and better positioning our commercial organization to support future growth. Our cost-reduction actions are contributing to year-over-year profit improvement, and we are advancing operational and commercial initiatives designed to position TriMas for sustainable growth while executing our plan to create long-term shareholder value and build a stronger TriMas for the future.
While our third quarter results did not fully reflect the benefits of these actions and were impacted by the temporary throughput challenges at Norris Cylinder, we are encouraged by the progress underway and the foundation we are building for improved performance over time.
We continue to monitor the impacts of ongoing geopolitical conditions, including the conflicts in the Middle East, on our supply chains and raw material costs. We are actively partnering with customers and suppliers to manage cost, supply chain and other geopolitical challenges which may impact our fourth quarter and full year 2026 financial results if they persist or intensify.
We believe our capital structure remains strong and that we have sufficient headroom under our financial covenants, and ample cash and available liquidity under our revolving credit facility, to meet our debt service, capital expenditure and other short-term and long-term obligations for the next 12 months and for the foreseeable future. Supported by a strong balance sheet and financial flexibility from the divestiture proceeds, we continue to take a disciplined and balanced approach to capital allocation. We plan to redeploy these proceeds in ways that we expect will enhance long-term value to our shareholders, employees and customers, including by prioritizing organic growth investments, pursuing strategically aligned acquisitions or repurchasing shares.
Impact of New Accounting Standards
See Note 2, "New Accounting Pronouncements," included in Part I, Item 1, "Notes to Consolidated Financial Statements," within this quarterly report on Form 10-Q.
Critical Accounting Policies
Certain of our accounting policies require the application of significant judgment by management in selecting the appropriate assumptions used in calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, our evaluation of business and macroeconomic trends, and information from other outside sources, as appropriate.
During the quarter ended September 30, 2026, there were no material changes to the items that we disclosed as our critical accounting policies in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the Annual Report on Form 10-K for the year ended December 31, 2025.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
In the normal course of business, we are exposed to market risk associated with fluctuations in foreign currency exchange rates. We are also subject to interest risk as it relates to long-term debt. See Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations," for details about our primary market risks, and the objectives and strategies used to manage these risks. Also see Note 10, "Long-term Debt," and Note 11, "Derivative Instruments," in Part I, Item 1, "Notes to Consolidated Financial Statements," included within this quarterly report on Form 10-Q for additional information.
Item 4. Controls and Procedures
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
Evaluation of disclosure controls and procedures
As of September 30, 2026, an evaluation was carried out by management, with the participation of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) pursuant to Rule 13a-15 of the Exchange Act. The Company's disclosure controls and procedures are designed only to provide reasonable assurance that they will meet their objectives. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2026, the Company's disclosure controls and procedures are effective to provide reasonable assurance that they would meet their objectives.
Changes in internal control over financial reporting
During the quarter ended September 30, 2026, the Company implemented OneStream, a new financial consolidation and reporting system, replacing the Company's legacy financial reporting system. Prior to the implementation, management executed a structured transition plan that included user acceptance testing, data migration reconciliations, and parallel close processes to support the integrity of financial data and the continuity of internal controls. The Company updated its internal controls to reflect changes to the financial reporting processes impacted by the implementation. Management continues to monitor the operation of the system and evaluate the design and operating effectiveness of the related internal controls over financial reporting.
Except for the implementation of OneStream described above, there have been no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
PART II. OTHER INFORMATION
TRIMAS CORPORATION
Item 1. Legal Proceedings
See Note 14, "Commitments and Contingencies," included in Part I, Item 1, "Notes to Consolidated Financial Statements," within this quarterly report on Form 10-Q.
Item 1A. Risk Factors
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A., "Risk Factors," in our 2025 Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. There have been no significant changes to our risk factors as disclosed in our 2025 Annual Report on Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about purchases made by the Company, or on behalf of the Company by an affiliated purchaser, of shares of the Company's common stock during the three months ended September 30, 2026:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Period | | Total Number of Shares Purchased | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) | | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (in millions) (1) |
| July 1, 2026 to July 31, 2026 | | — | | | $ | — | | | — | | | $ | 76.5 | |
| August 1, 2026 to August 31, 2026 | | 186,331 | | | $ | 40.10 | | | 186,331 | | | $ | 69.1 | |
| September 1, 2026 to September 30, 2026 | | 46,819 | | | $ | 38.38 | | | 46,819 | | | $ | 67.3 | |
| Total | | 233,150 | | | $ | 39.75 | | | 233,150 | | | $ | 67.3 | |
__________________________
(1) In February 2026, the Company announced its Board of Directors had authorized the Company to increase the purchase of its common stock up to $150 million in the aggregate, adding to the $48.9 million remaining under the previous authorization. The previous authorization, approved in November 2025, authorized up to $150 million of purchases in the aggregate of its common stock. Pursuant to this share repurchase program, during the three months ended September 30, 2026, the Company repurchased 233,150 shares of its common stock at a cost of $9.3 million. The share repurchase program is effective and has no expiration date.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
During the quarter ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
Adjustment of certain items in our unaudited consolidated financial statements as of and for the quarter ended September 30, 2026 included within our earnings release for the third quarter of 2026
We issued our earnings release for the three and nine months ended September 30, 2026, which was furnished to the Securities and Exchange Commission on October 29, 2026 in a Current Report on Form 8-K. Subsequent to the earnings release, management determined that certain balances required adjustment from those set forth in the earnings release. The balances that were adjusted, before consideration of income taxes, are inventories, accrued expenses and cost of sales. The impact of these adjustments is a decrease in the reported operating profit, and adjusted operating profit, for the three and nine months ended September 30, 2026 of $2.8 million, which represented a decrease in basic earnings per share of $0.06 and a decrease in diluted and adjusted earnings per share of $0.05. We have not amended, and do not intend to amend, our earnings release, and all required adjustments are included in this quarterly report on Form 10-Q
Item 6. Exhibits
Exhibits Index:
| | | | | |
| 3.1 | Fourth Amended and Restated Certificate of Incorporation of TriMas Corporation, incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on August 3, 2007. |
| 3.2 | Third Amended and Restated By-laws of TriMas Corporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 18, 2015. |
| 31.1 | Certification pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002. |
| 31.2 | Certification pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002. |
| 32.1 | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002. |
| 32.2 | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002. |
| 101 | The following materials from TriMas Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheet, (ii) the Consolidated Statement of Income, (iii) the Consolidated Statement of Comprehensive Income, (iv) the Consolidated Statement of Cash Flows, (v) the Consolidated Statement of Shareholders' Equity, (vi) Notes to Consolidated Financial Statements, and (vii) document and entity information. |
| |
| |
| |
| |
| |
| |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | | | | |
| | TRIMAS CORPORATION (Registrant) |
| | | | |
| | | | /s/ PAUL A. SWART |
| | | | |
| Date: | November 13, 2026 | By: | | Paul A. Swart Chief Financial Officer |